Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate

<!DOCTYPE html> <html lang="en" > <head > <meta charset="UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="HandheldFriendly" content="True" /> <meta name="MobileOptimized" content="320" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <link rel="stylesheet" href="/static/assets/style-70b9163a.css" /> <script type="module" crossorigin="" src="/static/assets/base_style-ec2bc71e.js"></script> <link rel="stylesheet" href="/static/assets/style-ef962842.css" /> <link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" /> <script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script> <style> @media screen and (min-width: 64em) { div.pmc-wm { background: repeat-y; background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E"); padding-left: 3rem; } } </style> <link rel="apple-touch-icon" sizes="180x180" href="/static/img/favicons/apple-touch-icon.png" /> <link rel="icon" type="image/png" sizes="48x48" href="/static/img/favicons/favicon-48x48.png" /> <link rel="icon" type="image/png" sizes="32x32" href="/static/img/favicons/favicon-32x32.png" /> <link rel="icon" type="image/png" sizes="16x16" href="/static/img/favicons/favicon-16x16.png" /> <link rel="manifest" href="/static/img/favicons/site.webmanifest" /> <link rel="mask-icon" href="/static/img/favicons/safari-pinned-tab.svg" color="#0071bc" /> <meta name="msapplication-config" content="/static/img/favicons/browserconfig.xml" /> <meta name="theme-color" content="#ffffff" /> <title> Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate - PMC </title>  <meta name="ncbi_app" content="cloudpmc-viewer" /> <meta name="ncbi_db" content="pmc" /> <meta name="ncbi_phid" content="E5FDA5627424B6D303A56200083F5C0E.m_1" />  <meta name="ncbi_pdid" content="article" /> <link rel="preconnect" href="https://www.google-analytics.com" /> <link rel="dns-prefetch" href="https://cdn.ncbi.nlm.nih.gov" /> <link rel="preconnect" href="https://code.jquery.com" /> <meta name="ncbi_domain" content="wjg"> <meta name="ncbi_type" content="fulltext"> <meta name="ncbi_pcid" content="journal"> <link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/"> <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"> <meta name="citation_journal_title" content="World Journal of Gastroenterology"> <meta name="citation_title" content="Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate"> <meta name="citation_author" content="Mariella Faccia"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy, mariellafaccia4@gmail.com"> <meta name="citation_author" content="Maria Elena Ainora"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_author" content="Francesca Romana Ponziani"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_author" content="Laura Riccardi"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_author" content="Matteo Garcovich"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_author" content="Antonio Gasbarrini"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_author" content="Maurizio Pompili"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_author" content="Maria Assunta Zocco"> <meta name="citation_author_institution" content="Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy"> <meta name="citation_publication_date" content="2019 Aug 21"> <meta name="citation_volume" content="25"> <meta name="citation_issue" content="31"> <meta name="citation_firstpage" content="4437"> <meta name="citation_doi" content="10.3748/wjg.v25.i31.4437"> <meta name="citation_pmid" content="31496623"> <meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/"> <meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/"> <meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/pdf/WJG-25-4437.pdf"> <meta name="description" content="Portal vein thrombosis (PVT) represents a well-known complication during the natural course of liver cirrhosis (LC), ranging from asymptomatic cases to life-threating conditions related to portal hypertension and hepatic decompensation. Portal flow ..."> <meta name="og:title" content="Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate"> <meta name="og:type" content="article"> <meta name="og:site_name" content="PubMed Central (PMC)"> <meta name="og:description" content="Portal vein thrombosis (PVT) represents a well-known complication during the natural course of liver cirrhosis (LC), ranging from asymptomatic cases to life-threating conditions related to portal hypertension and hepatic decompensation. Portal flow ..."> <meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/"> <meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@ncbi"> </head> <body > <a class="usa-skipnav " href="#main-content"> Skip to main content </a> <section class="usa-banner " aria-label="Official website of the United States government" > <div class="usa-accordion"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="grid-col-auto"> <img aria-hidden="true" class="usa-banner__header-flag" src="/static/img/us_flag.svg" alt="" /> </div> <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true"> <p class="usa-banner__header-text"> An official website of the United States government </p> <span class="usa-banner__header-action">Here's how you know</span> </div> <button type="button" class="usa-accordion__button usa-banner__button " aria-expanded="false" aria-controls="gov-banner-default" data-testid="storybook-django-banner" > <span class="usa-banner__button-text">Here's how you know</span> </button> </div> </header> <div class="usa-banner__content usa-accordion__content" id="gov-banner-default" hidden> <div class="grid-row grid-gap-lg"> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-dot-gov.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Official websites use .gov</strong> <br /> A <strong>.gov</strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-https.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Secure .gov websites use HTTPS</strong> <br /> A <strong>lock</strong> ( <span class="icon-lock"> <svg xmlns="http://www.w3.org/2000/svg" width="52" height="64" viewBox="0 0 52 64" class="usa-banner__lock-image" role="graphics-symbol" aria-labelledby="banner-lock-description" focusable="false"> <title id="banner-lock-title">Lock</title> <desc id="banner-lock-description"> Locked padlock icon </desc> <path fill="#000000" fill-rule="evenodd" d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" /> </svg> </span>) or <strong>https://</strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class="usa-overlay"> </div> <header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header > <div class="ncbi-header"> <div class="ncbi-header__container"> <a class="ncbi-header__logo-container" href="/"> <img alt=" PMC home page " class="ncbi-header__logo-image" src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" /> </a>  <button type="button" class="usa-menu-btn ncbi-header__hamburger-button " aria-label="Show menu" data-testid="navMenuButton" > <svg aria-hidden="true" class="ncbi-hamburger-icon" fill="none" focusable="false" height="21" viewBox="0 0 31 21" width="31" xmlns="http://www.w3.org/2000/svg"> <path clip-rule="evenodd" d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z" fill="#F1F1F1" fill-rule="evenodd" /> </svg> </button>  <div class="ncbi-header__desktop-buttons">  <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button " aria-expanded="false" aria-controls="search-field-desktop-navigation" aria-label="Show search overlay" data-testid="toggleSearchPanelButton" data-toggle-search-panel-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#search" /> </svg> Search </button>  <div class="ncbi-header__login-dropdown"> <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button " aria-expanded="false" aria-controls="login-dropdown-menu" aria-label="Show login menu" data-testid="toggleLoginMenuDropdown" data-desktop-login-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#person" /> </svg> <span data-login-dropdown-text>Log in</span>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow> <use xlink:href="/static/img/sprite.svg#expand_less" /> </svg>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow> <use xlink:href="/static/img/sprite.svg#expand_more" /> </svg> </button>  <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu" id="login-dropdown-menu" data-desktop-login-menu-dropdown hidden> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> <li class="usa-nav__submenu-item"> <button type="button" class="usa-button usa-button--outline ncbi-header__login-dropdown-logout-button " data-testid="desktopLogoutButton" data-desktop-logout-button > Log out </button> </li> </ul> </div> </div> </div> </div>  <div class="ncbi-search-panel ncbi--show-only-at-desktop" data-testid="searchPanel" data-header-search-panel hidden> <div class="ncbi-search-panel__container"> <form action="https://www.ncbi.nlm.nih.gov/search/all/" aria-describedby="search-field-desktop-navigation-help-text" autocomplete="off" class="usa-search usa-search--big ncbi-search-panel__form" data-testid="form" method="GET" role="search"> <label class="usa-sr-only" data-testid="label" for="search-field-desktop-navigation"> Search… </label> <input class="usa-input" data-testid="textInput" id="search-field-desktop-navigation" name="term" placeholder="Search NCBI" type="search" value="" /> <button type="submit" class="usa-button " data-testid="button" > <span class="usa-search__submit-text"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="usa-nav"> <p class="usa-sr-only" id="primary-navigation-sr-only-title"> Primary site navigation </p>  <button type="button" class="usa-nav__close ncbi-nav__close-button " aria-label="Close navigation menu" data-testid="navCloseButton" > <img src="/static/img/usa-icons/close.svg" alt="Close" /> </button>  <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6" role="search"> <label class="usa-sr-only" for="search-field"> Search </label> <input class="usa-input" id="search-field-mobile-navigation" type="search" placeholder="Search NCBI" name="search" /> <button type="submit" class="usa-button " >  <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==" class="usa-search__submit-icon" alt="Search" /> </button> </form>   <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop" data-mobile-login-menu hidden> <p class="ncbi-nav__mobile-login-menu-status"> Logged in as: <strong class="ncbi-nav__mobile-login-menu-email" data-mobile-login-email-text></strong> </p> <ul class="usa-nav__primary usa-accordion"> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> </ul> </div> <button type="button" class="usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop " data-testid="mobileLoginButton" data-mobile-login-button > Log in </button> </nav> </header> <section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box"> <div class="pmc-nav-container"> <div class="pmc-header__bar"> <div class="pmc-header__logo"> <a href="/" title="Home" aria-label="PMC Home"></a> </div> <button type="button" class="usa-button usa-button--unstyled pmc-header__search__button" aria-label="Open search" data-ga-category="search" data-ga-action="PMC" data-ga-label="pmc_search_panel_mobile" > <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#search"></use> </svg> <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="pmc-header__search"> <form class="usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form" autocomplete="off" role="search"> <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label> <span class="autoComplete_wrapper flex-1"> <input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search" type="search" name="term" data-autocomplete-url="/search/autocomplete/"/> </span> <button class="usa-button" type="submit" formaction="https://www.ncbi.nlm.nih.gov/pmc/" data-ga-category="search" data-ga-action="PMC" data-ga-label="PMC_search_button" > <span class="usa-search__submit-text">Search in PMC</span> <img src="/static/img/usa-icons-bg/search--white.svg" class="usa-search__submit-icon" alt="Search" /> </button> </form> <ul class="pmc-header__search__menu"> <li> <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search"> Advanced Search </a> </li> <li> <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list"> Journal List </a> </li> <li> <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link" data-ga-label="user guide"> User Guide </a> </li> </ul> </div> </div> </section> <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="6710174"> <div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary"> <div class="grid-row"> <div class="grid-col-fill display-flex"> <div class="display-flex"> <ul class="usa-list usa-list--unstyled usa-list--horizontal"> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open resources" data-extra-class="is-visible-resources" data-ga-category="resources_accordion" data-ga-action="click" data-ga-label="mobile_icon" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#more_vert"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <a href="https://doi.org/10.3748/wjg.v25.i31.4437" class="usa-link display-flex" role="button" target="_blank" rel="noreferrer noopener" aria-label="View on publisher site" data-ga-category="actions" data-ga-action="click" data-ga-label="publisher_link_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#launch"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <a href="pdf/WJG-25-4437.pdf" class="usa-link display-flex" role="button" aria-label="Download PDF" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button class="usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_mobile" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6710174%2F%23open-collections-dialog" data-in-collections="false" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button role="button" class="usa-button usa-button--unstyled citation-dialog-trigger display-flex" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_mobile" data-all-citations-url="/resources/citations/6710174/" data-citation-style="nlm" data-download-format-link="/resources/citations/6710174/export/" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> </button> </li> <li class="pmc-permalink display-flex"> <button type="button" class="usa-button usa-button--unstyled display-flex" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </div> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open article navigation" data-extra-class="is-visible-in-page" data-ga-category="actions" data-ga-action="open" data-ga-label="article_nav_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#list"></use> </svg> </button> </div> </div> </div> <div class="grid-container desktop:padding-left-6"> <div id="article-container" class="grid-row grid-gap"> <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content"> <div class="grid-container padding-left-0 padding-right-0"> <div class="grid-row desktop:margin-left-neg-6"> <div class="grid-col-12"> <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.<br/> Learn more: <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a> | <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/"> PMC Copyright Notice </a> </div> </div> </div> <div class="grid-row pmc-wm desktop:margin-left-neg-6">  <main id="main-content" class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0" > <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-wjg.gif" alt="World Journal of Gastroenterology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to World Journal of Gastroenterology" title="Link to World Journal of Gastroenterology" shape="default" href="http://www.wjgnet.com/1007-9327/archive.htm" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div> <div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">World J Gastroenterol</button></div>. 2019 Aug 21;25(31):4437–4451. doi: <a href="https://doi.org/10.3748/wjg.v25.i31.4437" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3748/wjg.v25.i31.4437</a> </div> <nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu"> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22World%20J%20Gastroenterol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li> <li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22World%20J%20Gastroenterol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22World%20J%20Gastroenterol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li> <li role="presentation"><a href="?term=%22World%20J%20Gastroenterol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li> </ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs"> <hgroup><h1>Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate</h1></hgroup><div class="cg p"> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faccia%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mariella Faccia</span></a><div hidden="hidden" id="id1"> <h3><span class="name western">Mariella Faccia</span></h3> <div class="p"> <sup>1</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy, mariellafaccia4@gmail.com</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faccia%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mariella Faccia</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ainora%20ME%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Maria Elena Ainora</span></a><div hidden="hidden" id="id2"> <h3><span class="name western">Maria Elena Ainora</span></h3> <div class="p"> <sup>2</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ainora%20ME%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria Elena Ainora</span></a> </div> </div> <sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ponziani%20FR%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Francesca Romana Ponziani</span></a><div hidden="hidden" id="id3"> <h3><span class="name western">Francesca Romana Ponziani</span></h3> <div class="p"> <sup>3</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ponziani%20FR%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesca Romana Ponziani</span></a> </div> </div> <sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Riccardi%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Laura Riccardi</span></a><div hidden="hidden" id="id4"> <h3><span class="name western">Laura Riccardi</span></h3> <div class="p"> <sup>4</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Riccardi%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura Riccardi</span></a> </div> </div> <sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garcovich%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Matteo Garcovich</span></a><div hidden="hidden" id="id5"> <h3><span class="name western">Matteo Garcovich</span></h3> <div class="p"> <sup>5</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garcovich%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matteo Garcovich</span></a> </div> </div> <sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gasbarrini%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Antonio Gasbarrini</span></a><div hidden="hidden" id="id6"> <h3><span class="name western">Antonio Gasbarrini</span></h3> <div class="p"> <sup>6</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gasbarrini%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antonio Gasbarrini</span></a> </div> </div> <sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pompili%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Maurizio Pompili</span></a><div hidden="hidden" id="id7"> <h3><span class="name western">Maurizio Pompili</span></h3> <div class="p"> <sup>7</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pompili%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maurizio Pompili</span></a> </div> </div> <sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zocco%20MA%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Maria Assunta Zocco</span></a><div hidden="hidden" id="id8"> <h3><span class="name western">Maria Assunta Zocco</span></h3> <div class="p"> <sup>8</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zocco%20MA%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria Assunta Zocco</span></a> </div> </div> <sup>8</sup> </div> <ul class="d-buttons inline-list"> <li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li> <li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li> <li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li> </ul> <div class="d-panels font-secondary-light"> <div id="aip_a" class="d-panel p" style="display: none"> <div class="p" id="aff1"> <sup>1</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy, mariellafaccia4@gmail.com</div> <div id="aff2"> <sup>2</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div id="aff3"> <sup>3</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div id="aff4"> <sup>4</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div id="aff5"> <sup>5</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div id="aff6"> <sup>6</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div id="aff7"> <sup>7</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div id="aff8"> <sup>8</sup>Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy</div> <div class="author-notes p"><div class="fn" id="fn1"> <sup>✉</sup><p class="display-inline">Author contributions: Faccia M and Zocco MA conceived, wrote and revised the article; Ainora ME, Ponziani FR, Riccardi L, Gasbarrini A and Pompili M critically revised manuscript content; Garcovich M revised manuscript content and language.</p> <p>Corresponding author: Mariella Faccia, MD, Academic Fellow, Doctor, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Largo A. Gemelli 8, Rome 00168, Italy. <span>mariellafaccia4@gmail.com</span></p> <p>Telephone: +39-3405457425</p> </div></div> </div> <div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2019 May 5; Revised 2019 Jul 8; Accepted 2019 Jul 19; Issue date 2019 Aug 21.</p></section></div></div> <div id="clp_a" class="d-panel p" style="display: none"> <div>©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.</div> <p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</p> <div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div> </div> </div> <div>PMCID: PMC6710174 PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31496623/" class="usa-link">31496623</a> </div> </div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2> <p>Portal vein thrombosis (PVT) represents a well-known complication during the natural course of liver cirrhosis (LC), ranging from asymptomatic cases to life-threating conditions related to portal hypertension and hepatic decompensation. Portal flow stasis, complex acquired hypercoagulable disorders and exogenous factors leading to endothelial dysfunction have emerged as key factors for PVT development. However, PVT occurrence remains unpredictable and many issues regarding its natural history, prognostic significance and treatment are still elusive. In particular although spontaneous resolution or disease stability occur in most cases of PVT, factors predisposing to disease progression or recurrence after spontaneous recanalization are not clarified as yet. Moreover, PVT impact on LC outcome is still debated, as PVT may represent itself a consequence of liver fibrosis and hepatic dysfunction progression. Anticoagulation and transjugular intrahepatic portosystemic shunt are considered safe and effective in this setting and are recommended in selected cases, even if the safer therapeutic option and the optimal therapy duration are still unknown. Nevertheless, their impact on mortality rates should be addressed more extensively. In this review we present the most debated questions regarding PVT, whose answers should come from prospective cohort studies and large sample-size randomized trials.</p> <section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Portal vein thrombosis, Liver cirrhosis, Hypercoagulability, Anticoagulation, Direct oral anticoagulants</p></section></section><hr class="headless"> <p><strong>Core tip:</strong> Portal vein thrombosis (PVT) represents a common and potential life-threating complication of liver cirrhosis. Anticoagulant therapy is advised in selected cases, in particular for liver transplant candidates. Despite the advanced knowledge in PVT pathogenesis and diagnosis, many issues regarding its natural history and prognostic outcome remain elusive. Likewise, the safer anticoagulant option, the potential role of direct oral anticoagulants and the optimal duration of therapy are still matter of debate. Given the clinical significance of this pathological entity, these cardinal issues should urgently be addressed in large prospective cohort studies and randomized trails.</p> <section id="sec1"><h2 class="pmc_sec_title">INTRODUCTION</h2> <p>Portal vein thrombosis (PVT) refers to blood clot formation within the trunk of the portal vein (PV) or its main branches, which may extend to the splenic and superior mesenteric veins (SMV). It can range from a partial and asymptomatic obstruction of the vessel to a complete blockade of portal venous blood flow, leading to hepatic decompensation, variceal bleeding and intestinal infarction secondary to portal hypertension (PH). PVT represents a well-known complication during the natural history of liver cirrhosis (LC), as a result of portal flow stasis, inherited or acquired prothrombotic disorders and/or vascular endothelial injury due to abdominal infection, surgery or trauma[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>,<a href="#B2" class="usa-link" aria-describedby="B2">2</a>].</p> <p>It occurs mainly in advanced stages of LC and in the presence of hepatocellular carcinoma (HCC). It is worth mentioning that cirrhotic patients with HCC may experience 2 types of PVT: “non-malignant” PVT, secondary to hemostatic disturbances superimposed by HCC, and “malignant” PVT, due to direct invasion of the PV by neoplastic cells. Since “malignant” PVT represents an established exclusion criteria for liver transplantation (LT), surgical resection and imaging-guided HCC treatments, early recognition of this entity is crucial for prognosis definition and decisions making[<a href="#B3" class="usa-link" aria-describedby="B3">3</a>].</p> <p>Although PVT in LC was first described almost 150 years ago and it has been widely studied in clinical and experimental studies, many issues regarding its pathogenesis, natural history, prevention and treatment are still matter of debate[<a href="#B4" class="usa-link" aria-describedby="B4">4</a>]. Which are the predisposing factors? What is the natural evolution of asymptomatic cases? Is PVT clinically significant on LC natural history or does it represent an epiphenomenon of advanced liver disease? What is the impact on patient outcome including those undergoing LT? Which patients should be treated and how long? Which anticoagulant could represent a safe therapeutic option? How long should therapy be extended in case of repermeation, give the risk of thrombosis recurrence? How much should anticoagulation (AC) be prolonged before considering therapy to have failed? This review aims to summarise the current knowledge on “non-malignant” PVT occurring in the setting of LC, with a focus on the aforementioned unanswered questions.</p></section><section id="sec2"><h2 class="pmc_sec_title">EPIDEMIOLOGY</h2> <p>PVT was first described in 1868 in a 20 years-old man, presenting with ascites, splenomegaly and esophageal varices (EV)[<a href="#B4" class="usa-link" aria-describedby="B4">4</a>]. Since then PVT in LC has been increasingly recognized due to amelioration of diagnostic imaging methods and better awareness amongst clinicians.</p> <p>The relative risk of developing PVT in the presence of LC is increased more than 7-fold above the risk observed in the general population[<a href="#B5" class="usa-link" aria-describedby="B5">5</a>]. In particular PVT prevalence increases with the degree of liver failure and in the setting of HCC, being as low as 1% in patients with compensated disease and rising to 8%-25% in candidates for LT and 40% in the presence of HCC[<a href="#B6" class="usa-link" aria-describedby="B6">6</a>,<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. Cirrhosis aetiology may also play a role in PVT development. Emerging data suggest that non-alcoholic steatohepatitis (NASH) may be an independent risk factor for significant thrombotic events, including PVT, in patients with decompensated cirrhosis[<a href="#B8" class="usa-link" aria-describedby="B8">8</a>,<a href="#B9" class="usa-link" aria-describedby="B9">9</a>]. Different diagnostic methods used in various studies may be responsible for prevalence data heterogeneity, which ranges from 0.6% to 16% in angiography or surgery studies to 10%-25% in ultrasound (US) studies[<a href="#B6" class="usa-link" aria-describedby="B6">6</a>]. Incidence of PVT in LC has been investigated in a limited number of reports. Values of 7.4% and 16% per year have been reported in small sample size studies involving patients with severe cirrhosis or listed for LT, respectively. One of the largest study performed in 1234 patients with compensated cirrhosis [Child-Turcotte-Pugh (CTP) A or B] reported a cumulative incidence of PVT of 4.6%, 8.2% and 10.7% at 1, 3 and 5 years, respectively[<a href="#B10" class="usa-link" aria-describedby="B10">10</a>,<a href="#B11" class="usa-link" aria-describedby="B11">11</a>].</p> <p>However, the retrospective design of most studies, the small sample size and the risk of underestimation of asymptomatic cases, do not allow definitive conclusions to be drawn. Recently, the multicenter prospective study PRO-LIVER (PVT relevance on LC: Italian venous thrombotic events registry), including 753 Caucasian cirrhotic patients (50% outpatient, 50% with mild severity disease), reported a prevalence of US-documented PVT of 17% (43% asymptomatic cases) and an annual incidence rate of 6.05%. Such incidence resulted much higher in patients with a history of PVT (18.9 per 100 patient-years <em>vs</em> 4.1 per 100 patient-years in those without prior PVT at admission) indicating that PVT per se carries a risk for recurrences[<a href="#B12" class="usa-link" aria-describedby="B12">12</a>,<a href="#B13" class="usa-link" aria-describedby="B13">13</a>].</p></section><section id="sec3"><h2 class="pmc_sec_title">PATHOPHYSIOLOGY</h2> <p>Venous stasis, hypercoagulability and endothelial dysfunction, summarized in the “Virchow triad”, are the 3 known pathophysiologic factors predisposing to thromboembolic events, including PVT. PV stasis secondary to liver architectural derangement is thought to play the main role in the setting of LC. We have found that a portal flow velocity lower than 15 cm/s at Doppler US is the most influential risk factor for PVT development in LC and our data were confirmed by another case-control study[<a href="#B11" class="usa-link" aria-describedby="B11">11</a>,<a href="#B14" class="usa-link" aria-describedby="B14">14</a>]. PV stasis may also be the result of a spontaneous portosystemic shunt causing a “steal” syndrome. In the study of Maruyama et al[<a href="#B15" class="usa-link" aria-describedby="B15">15</a>] the presence of collateral vessels with a flow volume of more than 400 mL/min and a flow velocity of more than 10 cm/s resulted a significant predictive factor for the occurrence of PVT in virus-induced cirrhosis. Since non-selective beta blockers (NSBB) act reducing PV inflow velocity and are extensively used for primary and secondary prevention of EV bleeding in LC, several studies have investigated their potential contribution to PVT development reporting conflicting results. No association between PVT and NSBBs treatment was reported by Violi et al[<a href="#B12" class="usa-link" aria-describedby="B12">12</a>], which confirmed a significant increase in PVT prevalence among patients with CTP class B and C, HCC, history of upper gastrointestinal bleeding or PVT, and older age. Conversely EV and NSBBs exposure resulted risk factors for PVT occurrence in other studies[<a href="#B16" class="usa-link" aria-describedby="B16">16</a>,<a href="#B17" class="usa-link" aria-describedby="B17">17</a>]. Although these results are in appearance conflicting, taken together they may suggest that the primary culprit of PVT may be the significant PH associated with more advanced liver disease which lead to NSBBs prescription, instead of NSBBs use per se. Future trials addressing the use of NSBBs in cirrhotic patients should include development of PVT as a specific safety outcome to allow definitive conclusions and comparisons between different types of NSBBs.</p> <p>Based on the presence of thrombocytopenia and prolongation of conventional coagulation tests, cirrhotic patients were traditionally considered “auto-anticoa-gulated”. However a growing body of clinical and laboratoristic evidence allowed to dispel this old dogma, showing a complete reassessment between pro- and anti-hemostatic drivers in LC (Table <a href="#T1" class="usa-link">1</a>), potentially leading to a hypercoagulation state, which is not expressed by routine coagulation tests[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>,<a href="#B7" class="usa-link" aria-describedby="B7">7</a>,<a href="#B18" class="usa-link" aria-describedby="B18">18</a>]. This hypothesis is supported by the evidence that thrombin generation in LC is normal or even increased compared to healthy subjects notwithstanding prothrombin time and activated partial thromboplastin time are prolonged[<a href="#B19" class="usa-link" aria-describedby="B19">19</a>,<a href="#B20" class="usa-link" aria-describedby="B20">20</a>]. Likewise, the reduction of platelet (PLT) number seems counterbalanced by PLT hyperractivity, as assessed by increased urinary excretion of 11-deydro-thromboxane B2 and by consistent elevation of p-selectin expression on PLT surface at rest and after thrombin stimulation and higher serum beta-thromboglobulin and platelet factor-4 alpha compared to controls[<a href="#B21" class="usa-link" aria-describedby="B21">21</a>,<a href="#B22" class="usa-link" aria-describedby="B22">22</a>]. It has been proposed that changes in PLT-von Willebrand factor (vWF) interaction, which is one of the first step of PLT adhesion, might compensate defects in PLT number and function. Higher molecular weight multimers of vWF have been extensively described in LC, as a result of reduced vWF cleaving protease ADAMTS-13, and seem to play a pivotal role in increasing PLT thrombogenic potential[<a href="#B23" class="usa-link" aria-describedby="B23">23</a>]. Although low serum ADAMTS-13 levels and activity were significantly associated with PVT development in cirrhotic patients irrespective of CTP and Model for end-stage liver disease (MELD) scores, further studies are needed to determine whether these parameters could be used in everyday clinical practice to predict PVT occurrence in LC[<a href="#B24" class="usa-link" aria-describedby="B24">24</a>,<a href="#B25" class="usa-link" aria-describedby="B25">25</a>].</p> <section class="tw xbox font-sm" id="T1"><h3 class="obj_head">Table 1.</h3> <div class="caption p"><p>Reassessment between anti- and pro-hemostatic drivers in liver cirrhosis</p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <thead align="center"><tr> <td align="left" rowspan="1" colspan="1"><strong>Hemostasis phase</strong></td> <td rowspan="1" colspan="1"><strong>Anti-hemostatic drivers</strong></td> <td rowspan="1" colspan="1"><strong>Pro-hemostatic drivers</strong></td> </tr></thead> <tbody align="center"> <tr> <td align="left" rowspan="1" colspan="1">Primary hemostasis (vasoconstriction and platelet plug formation)</td> <td rowspan="1" colspan="1">Thrombocytopenia</td> <td rowspan="1" colspan="1">Platelet hyperactivity High molecular weight multimers von Willebrand factor levels Low ADAM TS 13 levels and activity</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Secondary hemostasis (coagulation cascades)</td> <td rowspan="1" colspan="1">Low anticoagulant factors levels: AT, protein C and S High procoagulant factor levels: factor VIII</td> <td rowspan="1" colspan="1">Low procoagulant factors levels: fibrinogen, factor II, V, VII, IX, X, XI</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Tertiary hemostasis (fibrinolysis)</td> <td rowspan="1" colspan="1">Low plasminogen and high PAI levels</td> <td rowspan="1" colspan="1">High t-PA levels Low TAFI and plasmin inhibitor levels</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"><div class="fn" id="fn2"><p>AT: Antithrombin; ADAM TS 13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motif 13; PAI: Plasminogen activator inhibitor; t-PA: Tissue plasminogen activator; TAFI: Thrombin-activatable fibrinolysis inhibitor[<a href="#B18" class="usa-link" aria-describedby="B18">18</a>].</p></div></div></section><p>Concurrent thrombophilic conditions have been reported in 5.6% of patients with PVT and LC, however their contribution to PVT development is difficult to assess since they may be a secondary phenomenon of parenchymal liver disease rather than a primary disturbance[<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. Among different thrombophilic genetic defects, G20210A prothrombin gene variant has been the most common abnormality associated with PVT in patients with LC with a prevalence of 21.4%-29% and an odds ratio of 5.9 for development of PVT[<a href="#B26" class="usa-link" aria-describedby="B26">26</a>,<a href="#B27" class="usa-link" aria-describedby="B27">27</a>]. Another study demonstrated that a relevant proportion of cirrhotic patients with PVT harbours a myeloproliferative disorders secondary to JAK2 V617F mutation[<a href="#B28" class="usa-link" aria-describedby="B28">28</a>]. Other hypercoagulable risk factors may occur in patients with LC, but none results as definitive risk factor for PVT development[<a href="#B28" class="usa-link" aria-describedby="B28">28</a>,<a href="#B29" class="usa-link" aria-describedby="B29">29</a>].</p> <p>Furthermore, many poorly understood exogenous factors may act in the background of the above-mentioned prothrombic causes, tipping the balance towards thrombotic or bleeding complications. ‘‘Low-grade’’ endotoxemia, as a result of bacterial translocation from intestinal lumen to the portal circulation in advanced stage of LC, has been proposed as potential trigger of clotting system. Lipopolysaccharide derived from gut microbiota has been shown to increase endothelial release of factor VIII[<a href="#B30" class="usa-link" aria-describedby="B30">30</a>]. However, despite a clear correlation between endotoxemia and a marker of thrombin generation in LC, a study on 49 cirrhotic patients failed to demonstrate a correlation between both endotoxemia and platelet activity with PVT occurrence[<a href="#B31" class="usa-link" aria-describedby="B31">31</a>,<a href="#B32" class="usa-link" aria-describedby="B32">32</a>]. Anyway, the potential role of endotoxemia as prothrombotic trigger in the portal circulation of cirrhotic patients remains attractive and should be addressed more extensively in larger studies before drawing definitive conclusions. Among different LC etiologies, NASH is emerging as a potential risk factor for PVT, as it is associated with increased plasminogen activator inhibitor and reduced protein C levels[<a href="#B9" class="usa-link" aria-describedby="B9">9</a>]. If these findings will find confirmation, PVT occurrence might increase in the near future since NASH is becoming the leading cause of LC.</p> <p>Endoscopic therapy of bleeding EV (sclerotherapy and variceal band ligation), abdominal surgery, inflammation or trauma and vascular invasion by neoplastic cells (HCC, cholangiocarcinoma, hepatic metastasis) have been all proposed as potential determinants of PVT, due to direct vascular injury and disturbance of blood flow. PVT has been described in 16% of cirrhotic patients (70% with concomitant thrombophilic conditions) undergoing endoscopic therapy for EV after a mean follow-up period of 16 mo[<a href="#B26" class="usa-link" aria-describedby="B26">26</a>]. Opposite results were obtained by another prospective study performed in cirrhotic patients undergoing sclerotherapy for EV which failed to demonstrated an increased risk of PVT development[<a href="#B33" class="usa-link" aria-describedby="B33">33</a>]. Previous abdominal surgery and splenectomy have also been reported as risk factors for PVT. In particular splenectomy has been associated with a 10-fold increase in the risk of PVT development, independently of liver dysfunction severity, in a retrospective study involving 113 cirrhotic patients without malignancy[<a href="#B29" class="usa-link" aria-describedby="B29">29</a>,<a href="#B34" class="usa-link" aria-describedby="B34">34</a>,<a href="#B35" class="usa-link" aria-describedby="B35">35</a>].</p></section><section id="sec4"><h2 class="pmc_sec_title">PVT PREDICTION</h2> <p>The role of serum markers for PVT prediction in patients with LC remains elusive. A recent meta-analysis suggested that cirrhotic patients with PVT might have higher D-dimer concentrations than those without PVT and that postoperative D-dimer testing is worthwhile for the diagnosis of PVT after PH-related surgery. However, significant heterogeneity among studies limits generalizable conclusions[<a href="#B36" class="usa-link" aria-describedby="B36">36</a>]. Protein C and S levels have also been tested as potential predictor of PVT development without definite conclusions[<a href="#B11" class="usa-link" aria-describedby="B11">11</a>,<a href="#B37" class="usa-link" aria-describedby="B37">37</a>]. What is clear is that the true thrombotic potential in this group of patients is more complex than appreciated by measuring individual protein markers. Based on these evidence Sarin et al proposed a pre-test probability assessment for PVT prediction based on 10 criteria, 3 major (CTP class B or C; prior history of resolved PVT; prothrombotic risk factors such as factor V Leiden mutation, prothrombin gene mutation, MTHFR mutation) and 7 minor (evidence of a large portosystemic shunt or large isolated gastric varices; HCC; previous/or active systemic venous thrombotic events or abortions; acute abdomen; new onset or worsening PH complications; recent endoscopic, radiological or surgical abdominal interventions; portal flow velocity < 15 cm/s). Although attractive, this scoring system requires validation in prospective clinical studies[<a href="#B38" class="usa-link" aria-describedby="B38">38</a>].</p></section><section id="sec5"><h2 class="pmc_sec_title">DIAGNOSIS</h2> <p>In the majority of patients with cirrhosis, PVT is an incidental finding, during routine US, computed tomography or magnetic resonance imaging evaluation. In other cases diagnosis is made after a new event of hepatic decompensation or abdominal pain. The first-line technique for PVT detection is Doppler US, with sensitivity of about 90% for complete PVT and about 50% for partial PVT and high operator-dependence. Contrast-enhanced imaging techniques, including contrast-enhanced US, have comparable sensitivity for PVT diagnosis, allowing in addition a better definition of PVT extension as well as an evaluation of underlying malignancy and other sequelae[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>,<a href="#B2" class="usa-link" aria-describedby="B2">2</a>,<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. HCC proximity to PVT, enlargement of the PV > 23 mm, enhancement of the thrombus in the arterial phase of contrast enhanced imaging scan or PV arterial-like flow on Doppler US have been proposed as reliable radiologic criteria for “malignant” PVT, confining histologic confirmation to selected uncertain cases[<a href="#B3" class="usa-link" aria-describedby="B3">3</a>]. After PVT diagnosis, upper gastrointestinal endoscopy is warranted to assess the presence and degree of EV.</p></section><section id="sec6"><h2 class="pmc_sec_title">PVT NATURAL HISTORY</h2> <p>PVT encompasses 2 different entities: acute PVT and chronic PVT (also called portal cavernoma). They represent successive stages of the same disease, since acute PVT may be followed by lysis of the thrombus or cavernous transformation of PV, consisting in porto-portal collaterals formation within or around the thrombosed vessel in an effort to bypass venous obstruction[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>]. Changes related to cavernous transformation of PV have been described to occur already 6-20 d after acute PVT and are more common in patients without concomitant liver disease, since PV flow stasis in LC usually prevents collateral channel dilatation[<a href="#B39" class="usa-link" aria-describedby="B39">39</a>].</p> <p>The most common evolution of acute PVT is spontaneous resolution or disease stability, which have been described from 45% to over 70% of cases in different studies[<a href="#B9" class="usa-link" aria-describedby="B9">9</a>,<a href="#B40" class="usa-link" aria-describedby="B40">40</a>,<a href="#B41" class="usa-link" aria-describedby="B41">41</a>]. However, data regarding predictors of PVT natural course are very scarce. In particular no significant association has been found between thrombus age and PVT degree at diagnosis and spontaneous PV recanalization[<a href="#B40" class="usa-link" aria-describedby="B40">40</a>,<a href="#B42" class="usa-link" aria-describedby="B42">42</a>]. Likewise age, sex, severity of liver and renal function, EV, previous PH-related bleeding, ascites, location of thrombosis and portal cavernoma were no significant predictors for PVT resolution in another retrospective study[<a href="#B43" class="usa-link" aria-describedby="B43">43</a>]. Only Maruyama et al. demonstrated that the diameter and flow volume in the largest collateral vessel at the time of diagnosis of PVT were negatively associated with spontaneous improvement of PVT, however these data require prospective external validation[<a href="#B15" class="usa-link" aria-describedby="B15">15</a>].</p> <p>Recurrence of PVT after spontaneous recanalization has also been described in some cohort studies, ranging from 21.3% (19 of 89 patients, mean follow-up 47 mo) in the prospective cohort study by Nery et al[<a href="#B10" class="usa-link" aria-describedby="B10">10</a>] to 45% (9 of 20 patients, mean follow-up of 63.3 mo) in the retrospective study by Maruyama et al[<a href="#B10" class="usa-link" aria-describedby="B10">10</a>,<a href="#B15" class="usa-link" aria-describedby="B15">15</a>]. Considering the possibility of thrombus recurrence, the patients should continue to monitor the PV patency after spontaneous PV recanalization.</p></section><section id="sec7"><h2 class="pmc_sec_title">CLINICAL IMPACT ON CIRRHOSIS PROGRESSION AND OUTCOME</h2> <p>PVT occurrence is thought to have a negative impact on LC prognosis, because it produces a further increase in PH which may lead to potentially life-threatening bleeding events and worsening of liver function. However, contrary to common clinical belief, the actual prognostic value of PVT on liver disease progression and outcome remains an unsolved issue, since clinical studies are usually based on small cohorts of patients and short follow-up periods. D’Amico et al. prospectively reported a more than 3-fold higher risk of failure to control active variceal bleeding in cirrhotic patients with PVT, irrespective of treatment modality (endoscopic hemostasis or surgical shunting), whereas in a subsequent retrospective analysis Dell’Era et al[<a href="#B44" class="usa-link" aria-describedby="B44">44</a>,<a href="#B45" class="usa-link" aria-describedby="B45">45</a>] showed that PVT was associated with longer time to EV eradication (8 d difference) but not with treatment failure. It has been proposed that the non-occlusive nature of most PVT cases involved in the second study and the improvement achieved in gastrointestinal bleeding management could explain these conflicting results. The impact of PVT on multiple LC outcomes has been investigated in a recent meta-analysis involving 2436 cirrhotic participants[<a href="#B46" class="usa-link" aria-describedby="B46">46</a>]. The study reported a significant association of PVT with both mortality and ascitic decompensation, but did not evaluated the pooled effect of PVT on other markers of hepatic decompensation such as gastroesophageal variceal bleeding or hepatic encephalopathy due to data insufficiency[<a href="#B46" class="usa-link" aria-describedby="B46">46</a>]. On the contrary, a recent prospective multicenter study on LC outcome did not find a prognostic role of PVT (mainly non-occlusive) on either mortality and hepatic decompensation[<a href="#B10" class="usa-link" aria-describedby="B10">10</a>]. It should be considered that the small number of studies evaluated and the lack of randomized controlled trials limit meta-analysis conclusions generalization. Similar results were obtained by Qi et al[<a href="#B47" class="usa-link" aria-describedby="B47">47</a>], that, after conducting a systematic review of the literature, concluded that heterogeneity in data reporting and lengths of follow-up among studies did not allow to draw conclusions about PVT consequences on LC outcomes.</p> <p>Furthermore, it is worth mentioning that progression or regression of partial PVT seem to have no impact on LC natural history. In particular Luca et al[<a href="#B40" class="usa-link" aria-describedby="B40">40</a>] found that spontaneous improvement of PVT did not provide any benefit in terms of development of LC-related complications, LT and survival since CTP score at diagnosis was the only independent predictor of survival and hepatic decompensation on multivariate analysis. Based on these impressive findings, it has been speculated that PVT occurrence and LC progression may represent independent and synergistic phenomena resulting from the same pathophysiological mechanisms. In particular intrahepatic microvascular thrombosis secondary to hepatic necroinflammation may act as the key determinant of both diseases, leading to liver ischemia, cell death, loss of functioning hepatic mass and enhanced fibrogenesis, through a process, called “parenchymal extinction”, which ultimately leads to liver dysfunction, PH worsening and PVT occurrence[<a href="#B18" class="usa-link" aria-describedby="B18">18</a>,<a href="#B48" class="usa-link" aria-describedby="B48">48</a>]. This hypothesis is supported by the results of Villa et al[<a href="#B49" class="usa-link" aria-describedby="B49">49</a>] who reported that daily prophylactic dose of low molecular weight heparin (LMWH) for 12 mo prevented hepatic decompensation and PVT development in patients with compensated cirrhosis (CPT B7-C10) and conferred a significant survival benefit in the 5-years follow-up. The same authors postulated that LMWH protective effect on the course of the liver disease was mediated by an improvement in intestinal microcirculation and reduction in bacterial translocation and liver inflammation rather than by PVT prevention. These findings although impressive were not confirmed by other studies[<a href="#B49" class="usa-link" aria-describedby="B49">49</a>].</p></section><section id="sec8"><h2 class="pmc_sec_title">CLINICAL IMPACT ON LT OUTCOME</h2> <p>PVT prevalence among candidates awaiting LT varies from 2.1% to 26%, being unrecognized pre-operatively in up to 50% of cases[<a href="#B50" class="usa-link" aria-describedby="B50">50</a>-<a href="#B52" class="usa-link" aria-describedby="B52">52</a>]. Historically PVT poses relevant challenges during LT-surgery due to increase in technical complexity, operative time, blood transfusion requirements and intensive care unit/hospital stays, which may all negatively affect outcomes. In the last decades, improvement in medical and surgical strategies allowed to overcome most of previous mentioned difficulties and, as a consequence, PVT is no longer considered an absolute contraindication for LT[<a href="#B53" class="usa-link" aria-describedby="B53">53</a>]. In a retrospective study involving 191 patients undergoing LT between 2005 and 2014, the presence of pre-transplant PVT did not affect significantly the need of blood components transfusion and surgery time (except for severe grades of PVT), but was associated with higher, even if not statistically significant, 30-d mortality[<a href="#B54" class="usa-link" aria-describedby="B54">54</a>].</p> <p>To date the impact of PVT on morbidity and mortality after LT remains unclear, because the small number of published reports obtained controversial results and most of them did not differentiate between partial and occlusive PVT. According to the results of a recent metanalysis, the survival rates in this setting mainly depend on PVT type and surgical technique[<a href="#B50" class="usa-link" aria-describedby="B50">50</a>,<a href="#B51" class="usa-link" aria-describedby="B51">51</a>]. In particular, whereas incidentally discovered and partial PVT had a limited effect on post-LT outcomes, patients with complete PVT extending to distal superior SMV showed a lower 1-year survival rate with no impact on 5-year survival[<a href="#B50" class="usa-link" aria-describedby="B50">50</a>,<a href="#B51" class="usa-link" aria-describedby="B51">51</a>,<a href="#B55" class="usa-link" aria-describedby="B55">55</a>]. Furthermore, end-to-end PV anastomosis was associated with the same survival rates for patients with and without PVT regardless of its degree and extension, whereas non-anatomic portal anastomoses (cavoportal hemi-transposition; renoportal anastomosis; PV arterialization) were characterized by a worse prognosis[<a href="#B56" class="usa-link" aria-describedby="B56">56</a>,<a href="#B57" class="usa-link" aria-describedby="B57">57</a>]. Based on these data, it has been proposed that high selected LT-candidates with porto-mesenteric thrombosis should be addressed to transplant centres with large specific experience in PVT evaluation and management[<a href="#B51" class="usa-link" aria-describedby="B51">51</a>,<a href="#B56" class="usa-link" aria-describedby="B56">56</a>]. Indeed surgeon ability to establish a physiological portal anastomosis to the graft seems the most important factor in predicting patient outcome.</p> <p>The recurrence rate of PVT after LT has reduced from 36% in pioneering experiences to 2%-3% in recent years[<a href="#B53" class="usa-link" aria-describedby="B53">53</a>]. The rate of re-thrombosis has been ascribed to great degree and extension of pre-LT PVT, severe pre-LT PH and the need of PH-treatments, large portosystemic collaterals, mismatches in the size of the donor and the recipient PV, severe graft oedema, non-anatomical anastomosis, pediatric transplantation[<a href="#B58" class="usa-link" aria-describedby="B58">58</a>]. Post-LT PVT may significantly reduce both graft and patient survival and cause limitations or loss of future options for re-LT, particularly when these events occur intraoperatively or early after LT[<a href="#B59" class="usa-link" aria-describedby="B59">59</a>].</p></section><section id="sec9"><h2 class="pmc_sec_title">TREATMENT OPTIONS</h2> <p>Currently, robust data on the optimal management of PVT in the setting of LC are lacking and no definitive evidence-based recommendations have been reported in clinical guidelines or consensus conferences[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>,<a href="#B2" class="usa-link" aria-describedby="B2">2</a>,<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. Available strategies include AC therapy and, in some technically suitable patients, transjugular intrahepatic portosystemic shunt (TIPS). If no treatment is started, a close imaging surveillance is advised, but the best time frame to perform US-screening is still not well defined. However as patients with cirrhosis should undergo screening US for HCC every 6 months, assessment of the PV can be performed simultaneously without significant additional cost and is recommended[<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. In case of patients on wait-list for LT, time frame might be shortened to 3 months given the aforementioned potential implications on LT outcome and surgical planning[<a href="#B58" class="usa-link" aria-describedby="B58">58</a>].</p> <section id="sec10"><h3 class="pmc_sec_title">Anticoagulation</h3> <p>The utility of AC in patients awaiting LT is extensively shared. The rationale consists in achieving venous recanalization in case of thrombosis extending to the SMV or alternatively to prevent thrombus extension in the portal mesenteric junction, in order to allow conventional end-to-end PV anastomosis, which is associated with better outcomes in comparison with other surgical approaches[<a href="#B58" class="usa-link" aria-describedby="B58">58</a>,<a href="#B60" class="usa-link" aria-describedby="B60">60</a>]. In this setting AC leads to complete recanalization in about 40% of cases and should be prolonged until LT given the high rates of PVT recurrence after withdrawal[<a href="#B61" class="usa-link" aria-describedby="B61">61</a>,<a href="#B62" class="usa-link" aria-describedby="B62">62</a>]. No consensus exists concerning AC indication, dosage and duration after LT, however early post-operative AC with a short course of heparin is performed in many centres in high-risk liver recipients with an underlying prothrombotic state, especially in those undergoing “non-anatomical” procedures[<a href="#B56" class="usa-link" aria-describedby="B56">56</a>,<a href="#B63" class="usa-link" aria-describedby="B63">63</a>]. Conversely AC use for those patients who are not candidate to LT remains controversial, given the retrospective nature of most of the available data, the bleeding-related concerns and the heterogeneous rate of spontaneous recanalization, which makes it difficult to evaluate the real efficacy of different treatments. Experimental data suggest that AC my play an important role in patients with chronic liver disease, since it has been demonstrated that AC may prevent fibrogenesis through inhibition of fibrin and factor Xa in animal models[<a href="#B64" class="usa-link" aria-describedby="B64">64</a>,<a href="#B65" class="usa-link" aria-describedby="B65">65</a>].</p> <p>According to the recent European Association for the Study of the Liver and American Association for the Study of Liver Diseases guidelines, AC treatment is advised for at least 3-6 months in the presence of cirrhotic-PVT and should be continued for some months after PV repermeation or until transplant in LT candidates, while it might be continued lifelong in case of SMV thrombosis and intestinal infarction[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>,<a href="#B2" class="usa-link" aria-describedby="B2">2</a>]. A more prudent approach has been suggested by the 7th International Conference on Coagulation in Liver Disease, which recommends AC treatment for LT candidates with occlusive main PVT with or without proximal extension into the SMV and on a case by case basis and after multi-disciplinary discussion for high grade PVT in non-transplant population[<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. All guidelines underline the absolute need of gastroesophageal varices screening prior to AC therapy, in order to perform primary or secondary bleeding preventive strategies.</p> <p>Although LMWH and vitamin K antagonists (VKA) are considered the first choice for PVT treatment unrelated to cirrhosis, their role in cirrhotic patients remains still unclear. LMWH is commonly used in the acute setting and has the advantage of a fixed dose without laboratory monitoring; however, daily subcutaneous injections may reduce compliance and low levels of antithrombin III together with reduced glomerular filtration rate due to hepato-renal syndrome may require unpredictable dose adjustments. A recent study compared different doses of enoxaparin (1.5 mg/kg per 24 h <em>vs</em> 1 mg/kg per 12 h) for cirrhotic-PVT treatment showing comparable efficacy but a significantly higher rate of injection-site haemorrhage, epistaxis, or haematuria in the 1.5 mg/kg group[<a href="#B66" class="usa-link" aria-describedby="B66">66</a>]. VKAs are chosen for long-term AC but spontaneous INR prolongation and interference with MELD score make their use particularly challenging. Recently, the reduction of endogenous-thrombin-potential has shown reliability for AC monitoring in LC and may allow to overcome some of the above-mentioned limits in the near future[<a href="#B67" class="usa-link" aria-describedby="B67">67</a>]. Safety and efficacy issues of AC for cirrhotic-PVT treatment are still debated and have recently been addressed by 2 meta-analyses[<a href="#B68" class="usa-link" aria-describedby="B68">68</a>,<a href="#B69" class="usa-link" aria-describedby="B69">69</a>]. In the study of Qi X et al., involving 16 studies, LMWH and VKA were associated with acceptable major and minor bleeding rates (pooled rate 3.3%) and a relatively high rate of PV recanalization (pooled rate 66.6%, 41.5% for complete PV recanalization). However the inclusion of both comparative and non-comparative studies and the heterogeneity of outcome definitions does not allow to draw generalizable conclusions[<a href="#B68" class="usa-link" aria-describedby="B68">68</a>]. In the second meta-analysis performed on 8 studies with a total of 353 patients, PV recanalization was observed in 71% of patients treated with AC (<em>vs</em> 42% of untreated patients) with a complete recanalization rate of 53% (<em>vs</em> 33% of untreated patients). The same authors reported significantly lower rates of clot progression (9% <em>vs</em> 33%) in the AC group without differences in major or minor bleeding events between the 2 groups (11%)[<a href="#B69" class="usa-link" aria-describedby="B69">69</a>]. Although these results were encouraging, clinical and methodologic heterogeneity between studies, lack of prospective randomized studies and the inclusion of 2 studies involving patients undergoing invasive procedure for PH-treatment (TIPS placement and partial splenic embolization) suggest caution in clinical practice. To date, no clear predictors of efficacy have been established. In a recent prospective study involving 65 patients with PVT (72% non-occlusive) treated with LMWH, treatment efficacy was related to age of the thrombus and time interval (< 6 mo) between estimated thrombus onset and treatment start[<a href="#B70" class="usa-link" aria-describedby="B70">70</a>]. These results were consistent with a previous small report of Maruyama et al[<a href="#B71" class="usa-link" aria-describedby="B71">71</a>] who suggested that a positive intra-thrombus enhancement on CEUS, indicating a not completely organized thrombus, may be a potential indicator of successful recanalization in response to AC treatment.</p> <p>This controversial issue is further complicated by the lack of data about the impact of PVT resolution on patient survival in most of studies. In a retrospective analysis of 63 cirrhotic patients with PVT, complete PV recanalization secondary to VKA treatment carried a significant reduction in long-term risk of PH-related complication and need for LT[<a href="#B72" class="usa-link" aria-describedby="B72">72</a>]. Likewise a recent retrospective study on 182 cirrhotic patients with mild liver disfunction (13% CTP C) and PVT, showed that LMWH or VKA therapy was associated with higher survival rates in comparison with untreated patients during a median follow-up of 19 mo[<a href="#B73" class="usa-link" aria-describedby="B73">73</a>]. Another retrospective cohort of 80 patients, mainly in CTP B/C stage, with non-tumoral PVT, reported no influence of AC treatment on overall LT-free survival but a beneficial effect on LT-free survival among those with MELD ≥ 15 compared to untreated patients[<a href="#B74" class="usa-link" aria-describedby="B74">74</a>].</p> <p>Only one case-series study investigated the effect of fondaparinux 2.5 mg/day in acute PVT in 7 patients with decompensated LC. All patients were CTP class B–C, 6 with ascites and 2 with hepatic encephalopathy. The study showed that all patients had a recanalization of the PV after 7-21 d of treatment, and no side effects were reported[<a href="#B75" class="usa-link" aria-describedby="B75">75</a>].</p> <p>Direct oral anticoagulants (DOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), are attractive oral alternatives to VKA in many clinical settings. However, their role in cirrhotic patients is still unknown, since patients with remarkable liver disease have been excluded from most of the randomized clinical trials on DOACs. Indeed in this setting potential hepatotoxicity and unpredictable pharmacokinetics related to various degree of hepatic elimination (apixaban 75%, rivaroxaban 65%, edoxaban 50%, dabigatran 20%), cytochrome P450 and plasma protein binding levels alterations, overcame the advantages of no need of laboratory monitoring, rapid onset of action and oral formulation[<a href="#B76" class="usa-link" aria-describedby="B76">76</a>].</p> <p>However increasing safety data coming from small clinical studies and in vitro analyses renewed interest on DOACs use in the presence of compensated hepatic impairment. In a retrospective study involving 39 cirrhotic patients (CTP A and B) receiving DOACs (rivaroxaban or apixaban) or traditional AC (VKA and LMWH), bleeding events did not differ significantly between study groups and no drug-induced liver injury was documented over a 3-year period[<a href="#B77" class="usa-link" aria-describedby="B77">77</a>]. These results were in concordance with those of a previous meta-analysis, which suggested no increased risk of drug-induced liver injury with DOACs compared to conventional AC[<a href="#B78" class="usa-link" aria-describedby="B78">78</a>]. Likewise another retrospective study, including 27 patients on DOACs (rivaroxaban or apixaban) and 18 on VKA/LMWH, mainly in the CTP B stage, reported similar total bleeding events and significantly less major bleeding episodes in the DOACs group[<a href="#B79" class="usa-link" aria-describedby="B79">79</a>]. It is noteworthy to mention that small sample sizes and the limited number of CTP C patients restrict the applicability of these results in clinical practice and underline the need of larger prospective studies.</p> <p>Also DOACs efficacy for PVT treatment remains controversial, since available data come from case reports and series, mainly referring to rivaroxaban and apixaban use in compensated cirrhotic patients (Table <a href="#T2" class="usa-link">2</a>)[<a href="#B80" class="usa-link" aria-describedby="B80">80</a>-<a href="#B88" class="usa-link" aria-describedby="B88">88</a>]. Nagaoki et al[<a href="#B84" class="usa-link" aria-describedby="B84">84</a>] randomized 50 cirrhotic patients with variable CTP scores (29 A, 16 B, 5 C) and PVT to receive either VKA or edoxaban (dose adjusted to weight and creatinine clearance) for a total of 6 mo after 2 initial weeks of daparinoid sodium therapy. They reported a significantly higher PVT volume measured on CT in patients treated with VKA than in those receiving edoxaban and no significant differences regarding GI bleeding or other adverse effects among the 2 study arms. However the target INR of 1.5-2 in VKA group (inferior to the standard target of 2-3) and the absence of patients with CTP C in the group receiving edoxaban suggest caution when interpreting these results[<a href="#B84" class="usa-link" aria-describedby="B84">84</a>]. In addition a case report pointed out the efficacy of rivaroxaban in preventing PVT in LC, describing high-grade PVT occurrence in a 81 year-old woman with cryptogenic LC under treatment for chronic atrial fibrillation[<a href="#B85" class="usa-link" aria-describedby="B85">85</a>]. Based on current evidence and pending randomized controlled trials, it has been suggested that DOAC should be restricted to well compensated LC patients (CTP A and B) with platelet count > 50,000, after hematologic consultation[<a href="#B7" class="usa-link" aria-describedby="B7">7</a>].</p> <section class="tw xbox font-sm" id="T2"><h4 class="obj_head">Table 2.</h4> <div class="caption p"><p>Studies on direct oral anticoagulants efficacy and safety in cirrhotics with portal vein thrombosis</p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <thead align="center"><tr> <td align="left" rowspan="1" colspan="1"> <strong>Ref</strong>.</td> <td rowspan="1" colspan="1"><strong>Study design</strong></td> <td rowspan="1" colspan="1"><strong>No. of patients</strong></td> <td rowspan="1" colspan="1"><strong>Thrombosis extension</strong></td> <td rowspan="1" colspan="1"><strong>Drug and dosage</strong></td> <td rowspan="1" colspan="1"><strong>Duration (mo)</strong></td> <td rowspan="1" colspan="1"><strong>Outcome</strong></td> <td rowspan="1" colspan="1"><strong>Bleeding complication</strong></td> </tr></thead> <tbody align="center"> <tr> <td align="left" rowspan="1" colspan="1">Martinez et al[<a href="#B80" class="usa-link" aria-describedby="B80">80</a>]</td> <td rowspan="1" colspan="1">Case report</td> <td rowspan="1" colspan="1">1</td> <td rowspan="1" colspan="1">Complete PVT+ SMVT</td> <td rowspan="1" colspan="1">UFH (BT) + rivaroxaban 20 mg daily</td> <td rowspan="1" colspan="1">6</td> <td rowspan="1" colspan="1">Complete recanalization</td> <td rowspan="1" colspan="1">No</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Intagliata et al[<a href="#B81" class="usa-link" aria-describedby="B81">81</a>]</td> <td rowspan="1" colspan="1">Case series</td> <td rowspan="1" colspan="1">5</td> <td rowspan="1" colspan="1">3 PVT, 2 PVT + SMVT</td> <td rowspan="1" colspan="1">2 Rivaroxaban 20 mg daily (1 VKA as BT) 3 Apixaban 2.5 mg twice daily</td> <td rowspan="1" colspan="1">1-7</td> <td rowspan="1" colspan="1">Complete recanalization (2 treated with rivaroxaban) Stable (1 treated with apixaban) Unkown (2 other cases)</td> <td rowspan="1" colspan="1">No</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">De Gottardi et al[<a href="#B82" class="usa-link" aria-describedby="B82">82</a>]</td> <td rowspan="1" colspan="1">Prospective</td> <td rowspan="1" colspan="1">22</td> <td rowspan="1" colspan="1">N/A</td> <td rowspan="1" colspan="1">Rivaroxaban/Dabigatran/ Apixaban (60% VKA or LMWH as BT) mainly at lower dose</td> <td rowspan="1" colspan="1">14.6 (mean)</td> <td rowspan="1" colspan="1">N/A 1 recurrence of PVT with rivaroxaban</td> <td rowspan="1" colspan="1">1 major GI bleeding and 4 minor bleedings</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Yang et al[<a href="#B83" class="usa-link" aria-describedby="B83">83</a>]</td> <td rowspan="1" colspan="1">Case report</td> <td rowspan="1" colspan="1">1</td> <td rowspan="1" colspan="1">PVT</td> <td rowspan="1" colspan="1">Rivaroxaban 15 mg twice daily for 3 wk, then 20 mg daily</td> <td rowspan="1" colspan="1">6</td> <td rowspan="1" colspan="1">Complete recanalization</td> <td rowspan="1" colspan="1">No</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Nagakoky et al[<a href="#B84" class="usa-link" aria-describedby="B84">84</a>]</td> <td rowspan="1" colspan="1">Prospective</td> <td rowspan="1" colspan="1">20</td> <td rowspan="1" colspan="1">PVT</td> <td rowspan="1" colspan="1">Edoxaban 30 mg daily (16) or 60 mg daily (4) (2 wk of danaparoid sodium as BT)</td> <td rowspan="1" colspan="1">6</td> <td rowspan="1" colspan="1">Partial recanalization</td> <td rowspan="1" colspan="1">3 major GI bleedings</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Ponziani et al[<a href="#B85" class="usa-link" aria-describedby="B85">85</a>]</td> <td rowspan="1" colspan="1">Case report</td> <td rowspan="1" colspan="1">1</td> <td rowspan="1" colspan="1">PV and intrahepatic branches thrombosis</td> <td rowspan="1" colspan="1">Already on rivaroxaban 20 mg daily treatment, then LMWH</td> <td rowspan="1" colspan="1">N/A</td> <td rowspan="1" colspan="1">Portal cavernoma</td> <td rowspan="1" colspan="1">No</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Lenz et al[<a href="#B86" class="usa-link" aria-describedby="B86">86</a>]</td> <td rowspan="1" colspan="1">Case report</td> <td rowspan="1" colspan="1">1</td> <td rowspan="1" colspan="1">Partial PVT</td> <td rowspan="1" colspan="1">Rivaroxaban 10 mg daily</td> <td rowspan="1" colspan="1">5</td> <td rowspan="1" colspan="1">Complete recanalization (recurrence after withdrawal)</td> <td rowspan="1" colspan="1">No</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Qi et al[<a href="#B87" class="usa-link" aria-describedby="B87">87</a>]</td> <td rowspan="1" colspan="1">Case report</td> <td rowspan="1" colspan="1">1</td> <td rowspan="1" colspan="1">Occlusive SMVT SVT</td> <td rowspan="1" colspan="1">Rivaroxaban 15 mg daily for 1 mo then 10 mg daily</td> <td rowspan="1" colspan="1">3</td> <td rowspan="1" colspan="1">Partial</td> <td rowspan="1" colspan="1">Upper GI bleeding</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Pannach et al[<a href="#B88" class="usa-link" aria-describedby="B88">88</a>]</td> <td rowspan="1" colspan="1">Case report</td> <td rowspan="1" colspan="1">1</td> <td rowspan="1" colspan="1">PV and intrahepatic branches thrombosis</td> <td rowspan="1" colspan="1">Rivaroxaban 20 mg daily</td> <td rowspan="1" colspan="1">N/A</td> <td rowspan="1" colspan="1">Resolution</td> <td rowspan="1" colspan="1">No</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"><div class="fn" id="fn3"><p>UFH: Unfractionated heparin; VKA: Vitamin K antagonists; BT: Bridging therapy; LMWH: Low molecular weight heparin; PVT: Portal vein thrombosis; SMVT: Superior mesenteric vein thrombosis; SVT: Splenic vein thrombosis; GI: Gastrointestinal.</p></div></div></section></section><section id="sec11"><h3 class="pmc_sec_title">Transjugular intrahepatic portosystemic shunt</h3> <p>TIPS allows to create a low-resistance channel for portal venous flow between the hepatic vein and intrahepatic portion of the PV, through an expandable metal or polytetrafluoroethylene covered stent. It finds wide applications in PH-related complication of LC, such as refractory or recurrent variceal bleeding and refractory ascites[<a href="#B89" class="usa-link" aria-describedby="B89">89</a>]. TIPS placement with mechanical and/or pharmacologic thrombolysis represents also an attractive treatment option for PVT when AC is contraindicated or fails, but technical success of the procedure decreases in the presence of extended thrombosis or cavernous transformation of PV, so its use in these settings have been long discouraged. Recent interventional advances, including trans-hepatic or trans-splenic route beyond the standard trans-jugular access and refinement of stents, have increased procedure efficacy allowing to face always more complex cases[<a href="#B90" class="usa-link" aria-describedby="B90">90</a>]. Therefore nowadays TIPS represents a suitable solution for selected patients with symptomatic complete main PV thrombosis and significant PH, with or without PV cavernous transformation, with reported rates of re-canalization ranging from 60% to 92% depending on the vascular access technique[<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. In a recent meta-analysis of 13 studies (399 patients, 92% cirrhotic) TIPS (alone or in combination with catheter‐directed thrombolysis and/or thrombectomy) was feasible in 95% of cases, carried a moderate risk of major complications (10%, mainly when additional catheter directed thrombolysis was performed) and was highly effective in achieving sustained recanalization of PVT (81% of cirrhotic patients at 12 mo)[<a href="#B90" class="usa-link" aria-describedby="B90">90</a>]. In the evaluated studies PV re-thrombosis was not a frequent event after endovascular therapy and TIPS dysfunction was even less frequent, particularly with new covered stents. Noteworthy, the AC use post TIPS was associated with a non-significant higher pooled shunt patency rate (86% <em>vs</em> 83%), in accordance with previous studies[<a href="#B91" class="usa-link" aria-describedby="B91">91</a>,<a href="#B92" class="usa-link" aria-describedby="B92">92</a>]. These results are particularly attractive since TIPS alone, likely due to the high velocity flow created by the shunt, seems effective in maintaining long term PV patency, allowing to avoid AC treatment. Conversely SMV involvement, which has been associated with lower patency rate in many studies, might benefit from post-TIPS AC but further confirmations are required[<a href="#B90" class="usa-link" aria-describedby="B90">90</a>,<a href="#B91" class="usa-link" aria-describedby="B91">91</a>]. Moreover, TIPS placement resulted useful for PV revascularization as a bridge treatment to LT, and no association between shunt misplacement or occlusion and intra- or post-operative LT complication rates have been reported[<a href="#B93" class="usa-link" aria-describedby="B93">93</a>-<a href="#B96" class="usa-link" aria-describedby="B96">96</a>]. TIPS alone or in combination with percutaneous mechanical and/or pharmacologic thrombolysis resulted also safe and effective in selected cases of PVT post-LT not responsive to AC[<a href="#B97" class="usa-link" aria-describedby="B97">97</a>,<a href="#B98" class="usa-link" aria-describedby="B98">98</a>].</p></section></section><section id="sec12"><h2 class="pmc_sec_title">CONCLUSIONS</h2> <p>PVT is a common complication of LC, however its occurrence still remains elusive. More advanced stages of disease, previous history of PVT, concurrent thrombophilic genetic defects, venous stasis, HCC and recent endoscopic, radiological or surgical abdominal interventions have been proposed as the most reliable tools for PVT prediction, even if a pre-test scoring system is still lacking. Routine laboratory tests are unable to predict hemostatic balance in LC, while global coagulation assays, including thrombin generation tests and thromboelastography, although promising require validation in this clinical setting.</p> <p>Currently, robust data on the optimal management of PVT in the setting of LC are lacking because of studies and patients heterogeneity. If no treatment is started, a close US-surveillance is advised, with a time frame of 6 mo in asymptomatic patients and 3 mo in patients on wait-list for LT. Furthermore, gastroesophageal varices screening is recommended prior to AC therapy for primary or secondary bleeding preventive strategies. AC is certainly required for patients awaiting LT, since it allows venous recanalization in case of thrombosis extending to the SMV or prevents thrombus extension to the portal mesenteric junction, which complicates surgical procedure and is associated with worse outcomes. AC in non-transplant population with high-grade PVT is more controversial, given the lack of benefit on LC outcomes, and should be established on a case by case basis.</p> <p>LMWH and VKA are used for acute and long-term AC in LC, even if efficacy and safety data are not conclusive. DOACs use in LC population would be attractive but, pending randomized controlled trials, they should be restricted to well compensated patients after hematologic consultation. Interventional radiology, such as TIPS placement with mechanical and/or pharmacologic thrombolysis, represents also an attractive treatment option when AC is contraindicated or fails, but even if extended thrombosis or cavernous transformation of PV decrease technical success.</p> <p>Certainly many advances regarding PVT pathophysiology, natural history and treatment in LC have been made during the last decades. However, cardinal questions still remain unanswered. The answers to these questions should come from prospective cohort studies and randomized trials with large sample size, including detailed information about thrombus age, site and extension and a focus on short and long-term outcomes. Since these information could considerably change current clinical practice, the debate on PVT must go on.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2> <div class="fn-group p font-secondary-light font-sm"> <div class="fn p" id="fn4"><p>Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.</p></div> <div class="fn p" id="fn5"><p>Peer-review started: May 5, 2019</p></div> <div class="fn p" id="fn6"><p>First decision: June 10, 2019</p></div> <div class="fn p" id="fn7"><p>Article in press: July19, 2019</p></div> <div class="fn p" id="fn8"><p>Specialty type: Gastroenterology and hepatology</p></div> <div class="fn p" id="fn9"><p>Country of origin: Italy</p></div> <div class="fn p" id="fn10"><p>Peer-review report classification</p></div> <div class="fn p" id="fn11"><p>Grade A (Excellent): 0</p></div> <div class="fn p" id="fn12"><p>Grade B (Very good): B, B</p></div> <div class="fn p" id="fn13"><p>Grade C (Good): 0</p></div> <div class="fn p" id="fn14"><p>Grade D (Fair): 0</p></div> <div class="fn p" id="fn15"><p>Grade E (Poor): 0</p></div> <div class="fn p" id="fn16"><p>P-Reviewer: Kharlamov AN, Srivastava M S-Editor: Yan JP L-Editor: A E-Editor: Ma YJ</p></div> </div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2> <p>Mariella Faccia, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy, mariellafaccia4@gmail.com.</p> <p>Maria Elena Ainora, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p> <p>Francesca Romana Ponziani, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p> <p>Laura Riccardi, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p> <p>Matteo Garcovich, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p> <p>Antonio Gasbarrini, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p> <p>Maurizio Pompili, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p> <p>Maria Assunta Zocco, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome 00168, Italy.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2> <section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none"> <li id="B1"> <span class="label">1.</span><cite>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64:179–202. doi: 10.1016/j.jhep.2015.07.040.</cite> [<a href="https://doi.org/10.1016/j.jhep.2015.07.040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26516032/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&title=EASL%20Clinical%20Practice%20Guidelines:%20Vascular%20diseases%20of%20the%20liver&volume=64&publication_year=2016&pages=179-202&pmid=26516032&doi=10.1016/j.jhep.2015.07.040&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B2"> <span class="label">2.</span><cite>DeLeve LD, Valla DC, Garcia-Tsao G American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–1764. doi: 10.1002/hep.22772.</cite> [<a href="https://doi.org/10.1002/hep.22772" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6697263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19399912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Vascular%20disorders%20of%20the%20liver&author=LD%20DeLeve&author=DC%20Valla&author=G%20Garcia-Tsao&volume=49&publication_year=2009&pages=1729-1764&pmid=19399912&doi=10.1002/hep.22772&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B3"> <span class="label">3.</span><cite>Zanetto A, Campello E, Spiezia L, Burra P, Simioni P, Russo FP. Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. Cancers (Basel) 2018:10. doi: 10.3390/cancers10110450.</cite> [<a href="https://doi.org/10.3390/cancers10110450" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6266984/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30453547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&title=Cancer-Associated%20Thrombosis%20in%20Cirrhotic%20Patients%20with%20Hepatocellular%20Carcinoma&author=A%20Zanetto&author=E%20Campello&author=L%20Spiezia&author=P%20Burra&author=P%20Simioni&publication_year=2018&pages=10&pmid=30453547&doi=10.3390/cancers10110450&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B4"> <span class="label">4.</span><cite>Balfour GW, Stewart TG. Case of Enlarged Spleen Complicated with Ascites, Both Depending upon Varicose Dilatation and Thrombosis of the Portal Vein. Edinb Med J. 1869;14:589–598.</cite> [<a href="/articles/PMC5326991/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29639641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Edinb%20Med%20J&title=Case%20of%20Enlarged%20Spleen%20Complicated%20with%20Ascites,%20Both%20Depending%20upon%20Varicose%20Dilatation%20and%20Thrombosis%20of%20the%20Portal%20Vein&author=GW%20Balfour&author=TG%20Stewart&volume=14&publication_year=1869&pages=589-598&pmid=29639641&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B5"> <span class="label">5.</span><cite>Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12:2115–2119. doi: 10.3748/wjg.v12.i13.2115.</cite> [<a href="https://doi.org/10.3748/wjg.v12.i13.2115" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4087695/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16610067/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastroenterol&title=Portal%20vein%20thrombosis:%20Prevalence,%20patient%20characteristics%20and%20lifetime%20risk:%20A%20population%20study%20based%20on%2023,796%20consecutive%20autopsies&author=M%20Ogren&author=D%20Bergqvist&author=M%20Bj%C3%B6rck&author=S%20Acosta&author=H%20Eriksson&volume=12&publication_year=2006&pages=2115-2119&pmid=16610067&doi=10.3748/wjg.v12.i13.2115&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B6"> <span class="label">6.</span><cite>Ponziani FR, Zocco MA, Garcovich M, D'Aversa F, Roccarina D, Gasbarrini A. What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. World J Gastroenterol. 2012;18:5014–5020. doi: 10.3748/wjg.v18.i36.5014.</cite> [<a href="https://doi.org/10.3748/wjg.v18.i36.5014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3460326/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23049208/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastroenterol&title=What%20we%20should%20know%20about%20portal%20vein%20thrombosis%20in%20cirrhotic%20patients:%20A%20changing%20perspective&author=FR%20Ponziani&author=MA%20Zocco&author=M%20Garcovich&author=F%20D'Aversa&author=D%20Roccarina&volume=18&publication_year=2012&pages=5014-5020&pmid=23049208&doi=10.3748/wjg.v18.i36.5014&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B7"> <span class="label">7.</span><cite>Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F faculty of the 7th International Coagulation in Liver Disease. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018;118:1491–1506. doi: 10.1055/s-0038-1666861.</cite> [<a href="https://doi.org/10.1055/s-0038-1666861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6202935/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30060258/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Haemost&title=Concepts%20and%20Controversies%20in%20Haemostasis%20and%20Thrombosis%20Associated%20with%20Liver%20Disease:%20Proceedings%20of%20the%207th%20International%20Coagulation%20in%20Liver%20Disease%20Conference&author=NM%20Intagliata&author=CK%20Argo&author=JG%20Stine&author=T%20Lisman&author=SH%20Caldwell&volume=118&publication_year=2018&pages=1491-1506&pmid=30060258&doi=10.1055/s-0038-1666861&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B8"> <span class="label">8.</span><cite>Stine JG, Argo CK, Pelletier SJ, Maluf DG, Caldwell SH, Northup PG. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017;9:139–146. doi: 10.4254/wjh.v9.i3.139.</cite> [<a href="https://doi.org/10.4254/wjh.v9.i3.139" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5295147/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28217250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Hepatol&title=Advanced%20non-alcoholic%20steatohepatitis%20cirrhosis:%20A%20high-risk%20population%20for%20pre-liver%20transplant%20portal%20vein%20thrombosis&author=JG%20Stine&author=CK%20Argo&author=SJ%20Pelletier&author=DG%20Maluf&author=SH%20Caldwell&volume=9&publication_year=2017&pages=139-146&pmid=28217250&doi=10.4254/wjh.v9.i3.139&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B9"> <span class="label">9.</span><cite>Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl. 2015;21:1016–1021. doi: 10.1002/lt.24134.</cite> [<a href="https://doi.org/10.1002/lt.24134" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6615024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25845711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&title=Increased%20risk%20of%20portal%20vein%20thrombosis%20in%20patients%20with%20cirrhosis%20due%20to%20nonalcoholic%20steatohepatitis&author=JG%20Stine&author=NL%20Shah&author=CK%20Argo&author=SJ%20Pelletier&author=SH%20Caldwell&volume=21&publication_year=2015&pages=1016-1021&pmid=25845711&doi=10.1002/lt.24134&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B10"> <span class="label">10.</span><cite>Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla DC Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology. 2015;61:660–667. doi: 10.1002/hep.27546.</cite> [<a href="https://doi.org/10.1002/hep.27546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25284616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Causes%20and%20consequences%20of%20portal%20vein%20thrombosis%20in%201,243%20patients%20with%20cirrhosis:%20Results%20of%20a%20longitudinal%20study&author=F%20Nery&author=S%20Chevret&author=B%20Condat&author=E%20de%20Raucourt&author=L%20Boudaoud&volume=61&publication_year=2015&pages=660-667&pmid=25284616&doi=10.1002/hep.27546&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B11"> <span class="label">11.</span><cite>Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A. Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51:682–689. doi: 10.1016/j.jhep.2009.03.013.</cite> [<a href="https://doi.org/10.1016/j.jhep.2009.03.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19464747/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&title=Thrombotic%20risk%20factors%20in%20patients%20with%20liver%20cirrhosis:%20Correlation%20with%20MELD%20scoring%20system%20and%20portal%20vein%20thrombosis%20development&author=MA%20Zocco&author=E%20Di%20Stasio&author=R%20De%20Cristofaro&author=M%20Novi&author=ME%20Ainora&volume=51&publication_year=2009&pages=682-689&pmid=19464747&doi=10.1016/j.jhep.2009.03.013&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B12"> <span class="label">12.</span><cite>Violi F, Corazza GR, Caldwell SH, Perticone F, Gatta A, Angelico M, Farcomeni A, Masotti M, Napoleone L, Vestri A, Raparelli V, Basili S PRO-LIVER Collaborators. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Intern Emerg Med. 2016;11:1059–1066. doi: 10.1007/s11739-016-1416-8.</cite> [<a href="https://doi.org/10.1007/s11739-016-1416-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27026379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Intern%20Emerg%20Med&title=Portal%20vein%20thrombosis%20relevance%20on%20liver%20cirrhosis:%20Italian%20Venous%20Thrombotic%20Events%20Registry&author=F%20Violi&author=GR%20Corazza&author=SH%20Caldwell&author=F%20Perticone&author=A%20Gatta&volume=11&publication_year=2016&pages=1059-1066&pmid=27026379&doi=10.1007/s11739-016-1416-8&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B13"> <span class="label">13.</span><cite>Violi F, Corazza GR, Caldwell SH, Talerico G, Romiti GF, Napoleone L, Perticone F, Bolondi L, Pietrangelo A, Vestri AR, Raparelli V, Basili S PRO-LIVER Collaborative Group. Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. Thromb Haemost. 2019;119:496–499. doi: 10.1055/s-0038-1676981.</cite> [<a href="https://doi.org/10.1055/s-0038-1676981" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30616246/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Haemost&title=Incidence%20and%20Recurrence%20of%20Portal%20Vein%20Thrombosis%20in%20Cirrhotic%20Patients&author=F%20Violi&author=GR%20Corazza&author=SH%20Caldwell&author=G%20Talerico&author=GF%20Romiti&volume=119&publication_year=2019&pages=496-499&pmid=30616246&doi=10.1055/s-0038-1676981&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B14"> <span class="label">14.</span><cite>Stine JG, Wang J, Shah PM, Argo CK, Intagliata N, Uflacker A, Caldwell SH, Northup PG. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. Liver Int. 2018;38:94–101. doi: 10.1111/liv.13500.</cite> [<a href="https://doi.org/10.1111/liv.13500" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10540634/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28632958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Int&title=Decreased%20portal%20vein%20velocity%20is%20predictive%20of%20the%20development%20of%20portal%20vein%20thrombosis:%20A%20matched%20case-control%20study&author=JG%20Stine&author=J%20Wang&author=PM%20Shah&author=CK%20Argo&author=N%20Intagliata&volume=38&publication_year=2018&pages=94-101&pmid=28632958&doi=10.1111/liv.13500&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B15"> <span class="label">15.</span><cite>Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–574. doi: 10.1038/ajg.2012.452.</cite> [<a href="https://doi.org/10.1038/ajg.2012.452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23381015/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Gastroenterol&title=De%20novo%20portal%20vein%20thrombosis%20in%20virus-related%20cirrhosis:%20Predictive%20factors%20and%20long-term%20outcomes&author=H%20Maruyama&author=H%20Okugawa&author=M%20Takahashi&author=O%20Yokosuka&volume=108&publication_year=2013&pages=568-574&pmid=23381015&doi=10.1038/ajg.2012.452&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B16"> <span class="label">16.</span><cite>Nery F, Correia S, Macedo C, Gandara J, Lopes V, Valadares D, Ferreira S, Oliveira J, Gomes MT, Lucas R, Rautou PE, Miranda HP, Valla D. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: Results of a prospective longitudinal study. Aliment Pharmacol Ther. 2019;49:582–588. doi: 10.1111/apt.15137.</cite> [<a href="https://doi.org/10.1111/apt.15137" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30671978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aliment%20Pharmacol%20Ther&title=Nonselective%20beta-blockers%20and%20the%20risk%20of%20portal%20vein%20thrombosis%20in%20patients%20with%20cirrhosis:%20Results%20of%20a%20prospective%20longitudinal%20study&author=F%20Nery&author=S%20Correia&author=C%20Macedo&author=J%20Gandara&author=V%20Lopes&volume=49&publication_year=2019&pages=582-588&pmid=30671978&doi=10.1111/apt.15137&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B17"> <span class="label">17.</span><cite>Zampino R, Lebano R, Coppola N, Macera M, Grandone A, Rinaldi L, De Sio I, Tufano A, Stornaiuolo G, Adinolfi LE, Durante-Mangoni E, Battista GG, Niglio A. The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi J Gastroenterol. 2018;24:25–29. doi: 10.4103/sjg.SJG_100_17.</cite> [<a href="https://doi.org/10.4103/sjg.SJG_100_17" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5848320/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29451181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Saudi%20J%20Gastroenterol&title=The%20use%20of%20nonselective%20beta%20blockers%20is%20a%20risk%20factor%20for%20portal%20vein%20thrombosis%20in%20cirrhotic%20patients&author=R%20Zampino&author=R%20Lebano&author=N%20Coppola&author=M%20Macera&author=A%20Grandone&volume=24&publication_year=2018&pages=25-29&pmid=29451181&doi=10.4103/sjg.SJG_100_17&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B18"> <span class="label">18.</span><cite>Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147–156. doi: 10.1056/NEJMra1011170.</cite> [<a href="https://doi.org/10.1056/NEJMra1011170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21751907/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=The%20coagulopathy%20of%20chronic%20liver%20disease&author=A%20Tripodi&author=PM%20Mannucci&volume=365&publication_year=2011&pages=147-156&pmid=21751907&doi=10.1056/NEJMra1011170&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B19"> <span class="label">19.</span><cite>Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–558. doi: 10.1002/hep.20569.</cite> [<a href="https://doi.org/10.1002/hep.20569" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15726661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Evidence%20of%20normal%20thrombin%20generation%20in%20cirrhosis%20despite%20abnormal%20conventional%20coagulation%20tests&author=A%20Tripodi&author=F%20Salerno&author=V%20Chantarangkul&author=M%20Clerici&author=M%20Cazzaniga&volume=41&publication_year=2005&pages=553-558&pmid=15726661&doi=10.1002/hep.20569&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B20"> <span class="label">20.</span><cite>Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8:1994–2000. doi: 10.1111/j.1538-7836.2010.03937.x.</cite> [<a href="https://doi.org/10.1111/j.1538-7836.2010.03937.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20546119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Haemost&title=Enhanced%20thrombin%20generation%20in%20patients%20with%20cirrhosis-induced%20coagulopathy&author=A%20Gatt&author=A%20Riddell&author=V%20Calvaruso&author=EG%20Tuddenham&author=M%20Makris&volume=8&publication_year=2010&pages=1994-2000&pmid=20546119&doi=10.1111/j.1538-7836.2010.03937.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B21"> <span class="label">21.</span><cite>Davì G, Ferro D, Basili S, Iuliano L, Camastra C, Giammarresi C, Santarone S, Rocca B, Landolfi R, Ciabattoni G, Cordova C, Violi F. Increased thromboxane metabolites excretion in liver cirrhosis. Thromb Haemost. 1998;79:747–751.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9569186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Haemost&title=Increased%20thromboxane%20metabolites%20excretion%20in%20liver%20cirrhosis&author=G%20Dav%C3%AC&author=D%20Ferro&author=S%20Basili&author=L%20Iuliano&author=C%20Camastra&volume=79&publication_year=1998&pages=747-751&pmid=9569186&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B22"> <span class="label">22.</span><cite>Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J, Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology. 2001;48:818–822.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/11462931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatogastroenterology&title=Activation%20of%20blood%20platelets%20in%20chronic%20hepatitis%20and%20liver%20cirrhosis%20P-selectin%20expression%20on%20blood%20platelets%20and%20secretory%20activity%20of%20beta-thromboglobulin%20and%20platelet%20factor-4&author=A%20Panasiuk&author=D%20Prokopowicz&author=J%20Zak&author=J%20Matowicka-Karna&author=J%20Osada&volume=48&publication_year=2001&pages=818-822&pmid=11462931&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B23"> <span class="label">23.</span><cite>Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61. doi: 10.1002/hep.21231.</cite> [<a href="https://doi.org/10.1002/hep.21231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16799972/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Elevated%20levels%20of%20von%20Willebrand%20Factor%20in%20cirrhosis%20support%20platelet%20adhesion%20despite%20reduced%20functional%20capacity&author=T%20Lisman&author=TN%20Bongers&author=J%20Adelmeijer&author=HL%20Janssen&author=MP%20de%20Maat&volume=44&publication_year=2006&pages=53-61&pmid=16799972&doi=10.1002/hep.21231&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B24"> <span class="label">24.</span><cite>Lancellotti S, Basso M, Veca V, Sacco M, Riccardi L, Pompili M, De Cristofaro R. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: A pilot study. Intern Emerg Med. 2016;11:959–967. doi: 10.1007/s11739-016-1467-x.</cite> [<a href="https://doi.org/10.1007/s11739-016-1467-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27220954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Intern%20Emerg%20Med&title=Presence%20of%20portal%20vein%20thrombosis%20in%20liver%20cirrhosis%20is%20strongly%20associated%20with%20low%20levels%20of%20ADAMTS-13:%20A%20pilot%20study&author=S%20Lancellotti&author=M%20Basso&author=V%20Veca&author=M%20Sacco&author=L%20Riccardi&volume=11&publication_year=2016&pages=959-967&pmid=27220954&doi=10.1007/s11739-016-1467-x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B25"> <span class="label">25.</span><cite>Mikuła T, Kozłowska J, Stańczak W, Sapuła M, Różyk A, Wiercińska-Drapało A. Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis. Gastroenterol Res Pract. 2018;2018:3287491. doi: 10.1155/2018/3287491.</cite> [<a href="https://doi.org/10.1155/2018/3287491" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5937451/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29849584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterol%20Res%20Pract&title=Serum%20ADAMTS-13%20Levels%20as%20an%20Indicator%20of%20Portal%20Vein%20Thrombosis&author=T%20Miku%C5%82a&author=J%20Koz%C5%82owska&author=W%20Sta%C5%84czak&author=M%20Sapu%C5%82a&author=A%20R%C3%B3%C5%BCyk&volume=2018&publication_year=2018&pages=3287491&pmid=29849584&doi=10.1155/2018/3287491&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B26"> <span class="label">26.</span><cite>Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Sacco M, Martino R, De Nucci C, Mosca S, Iannaccone L, Ames PR, Romano L, Balzano A. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: Role of genetic thrombophilia. Endoscopy. 2002;34:535–538. doi: 10.1055/s-2002-33210.</cite> [<a href="https://doi.org/10.1055/s-2002-33210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12170404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endoscopy&title=Portal%20vein%20thrombosis%20after%20variceal%20endoscopic%20sclerotherapy%20in%20cirrhotic%20patients:%20Role%20of%20genetic%20thrombophilia&author=L%20Amitrano&author=V%20Brancaccio&author=MA%20Guardascione&author=M%20Margaglione&author=M%20Sacco&volume=34&publication_year=2002&pages=535-538&pmid=12170404&doi=10.1055/s-2002-33210&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B27"> <span class="label">27.</span><cite>Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, Karayalcin S, Ozden A, Bozkaya H, Yurdaydin C, Uzunalimoglu O. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol. 2005;17:339–343. doi: 10.1097/00042737-200503000-00013.</cite> [<a href="https://doi.org/10.1097/00042737-200503000-00013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15716659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Gastroenterol%20Hepatol&title=Thrombophilic%20gene%20mutations%20in%20cirrhotic%20patients%20with%20portal%20vein%20thrombosis&author=O%20Erkan&author=AM%20Bozdayi&author=S%20Disibeyaz&author=D%20Oguz&author=M%20Ozcan&volume=17&publication_year=2005&pages=339-343&pmid=15716659&doi=10.1097/00042737-200503000-00013&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B28"> <span class="label">28.</span><cite>Saugel B, Lee M, Feichtinger S, Hapfelmeier A, Schmid RM, Siveke JT. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. J Thromb Thrombolysis. 2015;40:54–60. doi: 10.1007/s11239-014-1124-z.</cite> [<a href="https://doi.org/10.1007/s11239-014-1124-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25115839/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Thrombolysis&title=Thrombophilic%20factor%20analysis%20in%20cirrhotic%20patients%20with%20portal%20vein%20thrombosis&author=B%20Saugel&author=M%20Lee&author=S%20Feichtinger&author=A%20Hapfelmeier&author=RM%20Schmid&volume=40&publication_year=2015&pages=54-60&pmid=25115839&doi=10.1007/s11239-014-1124-z&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B29"> <span class="label">29.</span><cite>Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40:736–741. doi: 10.1016/j.jhep.2004.01.001.</cite> [<a href="https://doi.org/10.1016/j.jhep.2004.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15094219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&title=Risk%20factors%20and%20clinical%20presentation%20of%20portal%20vein%20thrombosis%20in%20patients%20with%20liver%20cirrhosis&author=L%20Amitrano&author=MA%20Guardascione&author=V%20Brancaccio&author=M%20Margaglione&author=F%20Manguso&volume=40&publication_year=2004&pages=736-741&pmid=15094219&doi=10.1016/j.jhep.2004.01.001&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B30"> <span class="label">30.</span><cite>Carnevale R, Raparelli V, Nocella C, Bartimoccia S, Novo M, Severino A, De Falco E, Cammisotto V, Pasquale C, Crescioli C, Scavalli AS, Riggio O, Basili S, Violi F. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol. 2017;67:950–956. doi: 10.1016/j.jhep.2017.07.002.</cite> [<a href="https://doi.org/10.1016/j.jhep.2017.07.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28716745/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&title=Gut-derived%20endotoxin%20stimulates%20factor%20VIII%20secretion%20from%20endothelial%20cells.%20Implications%20for%20hypercoagulability%20in%20cirrhosis&author=R%20Carnevale&author=V%20Raparelli&author=C%20Nocella&author=S%20Bartimoccia&author=M%20Novo&volume=67&publication_year=2017&pages=950-956&pmid=28716745&doi=10.1016/j.jhep.2017.07.002&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B31"> <span class="label">31.</span><cite>Violi F, Ferro D, Basili S, Lionetti R, Rossi E, Merli M, Riggio O, Bezzi M, Capocaccia L. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost. 1997;77:44–47.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9031447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Haemost&title=Ongoing%20prothrombotic%20state%20in%20the%20portal%20circulation%20of%20cirrhotic%20patients&author=F%20Violi&author=D%20Ferro&author=S%20Basili&author=R%20Lionetti&author=E%20Rossi&volume=77&publication_year=1997&pages=44-47&pmid=9031447&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B32"> <span class="label">32.</span><cite>Wosiewicz P, Żorniak M, Hartleb M, Barański K, Hartleb M, Onyszczuk M, Pilch-Kowalczyk J, Kyrcz-Krzemień S. Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability. Clin Res Hepatol Gastroenterol. 2016;40:722–729. doi: 10.1016/j.clinre.2016.03.008.</cite> [<a href="https://doi.org/10.1016/j.clinre.2016.03.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27160816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Res%20Hepatol%20Gastroenterol&title=Portal%20vein%20thrombosis%20in%20cirrhosis%20is%20not%20associated%20with%20intestinal%20barrier%20disruption%20or%20increased%20platelet%20aggregability&author=P%20Wosiewicz&author=M%20%C5%BBorniak&author=M%20Hartleb&author=K%20Bara%C5%84ski&author=M%20Hartleb&volume=40&publication_year=2016&pages=722-729&pmid=27160816&doi=10.1016/j.clinre.2016.03.008&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B33"> <span class="label">33.</span><cite>Politoske D, Ralls P, Korula J. Portal vein thrombosis following endoscopic variceal sclerotherapy. Prospective controlled comparison in patients with cirrhosis. Dig Dis Sci. 1996;41:185–190. doi: 10.1007/BF02208603.</cite> [<a href="https://doi.org/10.1007/BF02208603" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8565755/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dig%20Dis%20Sci&title=Portal%20vein%20thrombosis%20following%20endoscopic%20variceal%20sclerotherapy.%20Prospective%20controlled%20comparison%20in%20patients%20with%20cirrhosis&author=D%20Politoske&author=P%20Ralls&author=J%20Korula&volume=41&publication_year=1996&pages=185-190&pmid=8565755&doi=10.1007/BF02208603&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B34"> <span class="label">34.</span><cite>Bagheri Lankarani K, Homayon K, Motevalli D, Heidari ST, Alavian SM, Malek-Hosseini SA. Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran. Hepat Mon. 2015;15:e26407. doi: 10.5812/hepatmon.26407.</cite> [<a href="https://doi.org/10.5812/hepatmon.26407" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4779252/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26977162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepat%20Mon&title=Risk%20Factors%20for%20Portal%20Vein%20Thrombosis%20in%20Patients%20With%20Cirrhosis%20Awaiting%20Liver%20Transplantation%20in%20Shiraz,%20Iran&author=K%20Bagheri%20Lankarani&author=K%20Homayon&author=D%20Motevalli&author=ST%20Heidari&author=SM%20Alavian&volume=15&publication_year=2015&pages=e26407&pmid=26977162&doi=10.5812/hepatmon.26407&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B35"> <span class="label">35.</span><cite>Qi X, Han G, Ye C, Zhang Y, Dai J, Peng Y, Deng H, Li J, Hou F, Ning Z, Zhao J, Zhang X, Wang R, Guo X. Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis Patients. Med Sci Monit. 2016;22:2528–2550. doi: 10.12659/MSM.898866.</cite> [<a href="https://doi.org/10.12659/MSM.898866" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4962757/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27432511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med%20Sci%20Monit&title=Splenectomy%20Causes%2010-Fold%20Increased%20Risk%20of%20Portal%20Venous%20System%20Thrombosis%20in%20Liver%20Cirrhosis%20Patients&author=X%20Qi&author=G%20Han&author=C%20Ye&author=Y%20Zhang&author=J%20Dai&volume=22&publication_year=2016&pages=2528-2550&pmid=27432511&doi=10.12659/MSM.898866&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B36"> <span class="label">36.</span><cite>Dai J, Qi X, Li H, Guo X. Role of D-dimer in the Development of Portal Vein Thrombosis in Liver Cirrhosis: A Meta-analysis. Saudi J Gastroenterol. 2015;21:165–174. doi: 10.4103/1319-3767.157567.</cite> [<a href="https://doi.org/10.4103/1319-3767.157567" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4455147/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26021776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Saudi%20J%20Gastroenterol&title=Role%20of%20D-dimer%20in%20the%20Development%20of%20Portal%20Vein%20Thrombosis%20in%20Liver%20Cirrhosis:%20A%20Meta-analysis&author=J%20Dai&author=X%20Qi&author=H%20Li&author=X%20Guo&volume=21&publication_year=2015&pages=165-174&pmid=26021776&doi=10.4103/1319-3767.157567&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B37"> <span class="label">37.</span><cite>Zhang D, Hao J, Yang N. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis. J Gastroenterol Hepatol. 2010;25:116–121. doi: 10.1111/j.1440-1746.2009.05921.x.</cite> [<a href="https://doi.org/10.1111/j.1440-1746.2009.05921.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19686413/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Gastroenterol%20Hepatol&title=Protein%20C%20and%20D-dimer%20are%20related%20to%20portal%20vein%20thrombosis%20in%20patients%20with%20liver%20cirrhosis&author=D%20Zhang&author=J%20Hao&author=N%20Yang&volume=25&publication_year=2010&pages=116-121&pmid=19686413&doi=10.1111/j.1440-1746.2009.05921.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B38"> <span class="label">38.</span><cite>Sarin SK, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, Valla DC. Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. Gastroenterology. 2016;151:574–577.e3. doi: 10.1053/j.gastro.2016.08.033.</cite> [<a href="https://doi.org/10.1053/j.gastro.2016.08.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27575821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&title=Toward%20a%20Comprehensive%20New%20Classification%20of%20Portal%20Vein%20Thrombosis%20in%20Patients%20With%20Cirrhosis&author=SK%20Sarin&author=CA%20Philips&author=PS%20Kamath&author=A%20Choudhury&author=H%20Maruyama&volume=151&publication_year=2016&pages=574-577.e3&pmid=27575821&doi=10.1053/j.gastro.2016.08.033&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B39"> <span class="label">39.</span><cite>De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K. Cavernous transformation of the portal vein: Patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. AJR Am J Roentgenol. 1995;165:1151–1155. doi: 10.2214/ajr.165.5.7572494.</cite> [<a href="https://doi.org/10.2214/ajr.165.5.7572494" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7572494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AJR%20Am%20J%20Roentgenol&title=Cavernous%20transformation%20of%20the%20portal%20vein:%20Patterns%20of%20intrahepatic%20and%20splanchnic%20collateral%20circulation%20detected%20with%20Doppler%20sonography&author=AM%20De%20Gaetano&author=M%20Lafortune&author=H%20Patriquin&author=A%20De%20Franco&author=B%20Aubin&volume=165&publication_year=1995&pages=1151-1155&pmid=7572494&doi=10.2214/ajr.165.5.7572494&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B40"> <span class="label">40.</span><cite>Luca A, Caruso S, Milazzo M, Marrone G, Mamone G, Crinò F, Maruzzelli L, Miraglia R, Floridia G, Vizzini G. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265:124–132. doi: 10.1148/radiol.12112236.</cite> [<a href="https://doi.org/10.1148/radiol.12112236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22891357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&title=Natural%20course%20of%20extrahepatic%20nonmalignant%20partial%20portal%20vein%20thrombosis%20in%20patients%20with%20cirrhosis&author=A%20Luca&author=S%20Caruso&author=M%20Milazzo&author=G%20Marrone&author=G%20Mamone&volume=265&publication_year=2012&pages=124-132&pmid=22891357&doi=10.1148/radiol.12112236&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B41"> <span class="label">41.</span><cite>Girleanu I, Stanciu C, Cojocariu C, Boiculese L, Singeap AM, Trifan A. Natural course of nonmalignant partial portal vein thrombosis in cirrhotic patients. Saudi J Gastroenterol. 2014;20:288–292. doi: 10.4103/1319-3767.141687.</cite> [<a href="https://doi.org/10.4103/1319-3767.141687" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4196343/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25253363/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Saudi%20J%20Gastroenterol&title=Natural%20course%20of%20nonmalignant%20partial%20portal%20vein%20thrombosis%20in%20cirrhotic%20patients&author=I%20Girleanu&author=C%20Stanciu&author=C%20Cojocariu&author=L%20Boiculese&author=AM%20Singeap&volume=20&publication_year=2014&pages=288-292&pmid=25253363&doi=10.4103/1319-3767.141687&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B42"> <span class="label">42.</span><cite>Garcovich M, Zocco MA, Ainora ME, Annicchiarico BE, Ponziani FR, Cesario V, Campanale M, Gigante G, Siciliano M, Gasbarrini A. Clinical outcome of portal vein thrombosis in cirrhotic patients: To observe or to treat? Hepatology. 2011;54:1261A–1262A.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Clinical%20outcome%20of%20portal%20vein%20thrombosis%20in%20cirrhotic%20patients:%20To%20observe%20or%20to%20treat?&author=M%20Garcovich&author=MA%20Zocco&author=ME%20Ainora&author=BE%20Annicchiarico&author=FR%20Ponziani&volume=54&publication_year=2011&pages=1261A%E2%80%931262A&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B43"> <span class="label">43.</span><cite>Chen H, Liu L, Qi X, He C, Wu F, Fan D, Han G. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016;28:82–89. doi: 10.1097/MEG.0000000000000482.</cite> [<a href="https://doi.org/10.1097/MEG.0000000000000482" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26513611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Gastroenterol%20Hepatol&title=Efficacy%20and%20safety%20of%20anticoagulation%20in%20more%20advanced%20portal%20vein%20thrombosis%20in%20patients%20with%20liver%20cirrhosis&author=H%20Chen&author=L%20Liu&author=X%20Qi&author=C%20He&author=F%20Wu&volume=28&publication_year=2016&pages=82-89&pmid=26513611&doi=10.1097/MEG.0000000000000482&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B44"> <span class="label">44.</span><cite>D'Amico G, De Franchis R Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612. doi: 10.1053/jhep.2003.50385.</cite> [<a href="https://doi.org/10.1053/jhep.2003.50385" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12939586/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Upper%20digestive%20bleeding%20in%20cirrhosis.%20Post-therapeutic%20outcome%20and%20prognostic%20indicators&author=G%20D'Amico&author=R%20De%20Franchis&volume=38&publication_year=2003&pages=599-612&pmid=12939586&doi=10.1053/jhep.2003.50385&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B45"> <span class="label">45.</span><cite>Dell'Era A, Iannuzzi F, Fabris FM, Fontana P, Reati R, Grillo P, Aghemo A, de Franchis R, Primignani M. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig Liver Dis. 2014;46:152–156. doi: 10.1016/j.dld.2013.08.138.</cite> [<a href="https://doi.org/10.1016/j.dld.2013.08.138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24084343/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dig%20Liver%20Dis&title=Impact%20of%20portal%20vein%20thrombosis%20on%20the%20efficacy%20of%20endoscopic%20variceal%20band%20ligation&author=A%20Dell'Era&author=F%20Iannuzzi&author=FM%20Fabris&author=P%20Fontana&author=R%20Reati&volume=46&publication_year=2014&pages=152-156&pmid=24084343&doi=10.1016/j.dld.2013.08.138&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B46"> <span class="label">46.</span><cite>Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, Northup PG. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. World J Hepatol. 2015;7:2774–2780. doi: 10.4254/wjh.v7.i27.2774.</cite> [<a href="https://doi.org/10.4254/wjh.v7.i27.2774" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4663397/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26644821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Hepatol&title=Portal%20vein%20thrombosis,%20mortality%20and%20hepatic%20decompensation%20in%20patients%20with%20cirrhosis:%20A%20meta-analysis&author=JG%20Stine&author=PM%20Shah&author=SL%20Cornella&author=SR%20Rudnick&author=MS%20Ghabril&volume=7&publication_year=2015&pages=2774-2780&pmid=26644821&doi=10.4254/wjh.v7.i27.2774&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B47"> <span class="label">47.</span><cite>Qi X, Dai J, Yang M, Ren W, Jia J, Guo X. Association between Portal Vein Thrombosis and Survival in Non-Liver-Transplant Patients with Liver Cirrhosis: A Systematic Review of the Literature. Gastroenterol Res Pract. 2015;2015:480842. doi: 10.1155/2015/480842.</cite> [<a href="https://doi.org/10.1155/2015/480842" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4355112/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25810714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterol%20Res%20Pract&title=Association%20between%20Portal%20Vein%20Thrombosis%20and%20Survival%20in%20Non-Liver-Transplant%20Patients%20with%20Liver%20Cirrhosis:%20A%20Systematic%20Review%20of%20the%20Literature&author=X%20Qi&author=J%20Dai&author=M%20Yang&author=W%20Ren&author=J%20Jia&volume=2015&publication_year=2015&pages=480842&pmid=25810714&doi=10.1155/2015/480842&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B48"> <span class="label">48.</span><cite>Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: Coagulation and hepatic fibrogenesis. Clin Liver Dis. 2009;13:117–126. doi: 10.1016/j.cld.2008.09.013.</cite> [<a href="https://doi.org/10.1016/j.cld.2008.09.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19150316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Liver%20Dis&title=Parenchymal%20extinction:%20Coagulation%20and%20hepatic%20fibrogenesis&author=QM%20Anstee&author=M%20Wright&author=R%20Goldin&author=MR%20Thursz&volume=13&publication_year=2009&pages=117-126&pmid=19150316&doi=10.1016/j.cld.2008.09.013&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B49"> <span class="label">49.</span><cite>Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–1260.e4. doi: 10.1053/j.gastro.2012.07.018.</cite> [<a href="https://doi.org/10.1053/j.gastro.2012.07.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22819864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&title=Enoxaparin%20prevents%20portal%20vein%20thrombosis%20and%20liver%20decompensation%20in%20patients%20with%20advanced%20cirrhosis&author=E%20Villa&author=C%20Camm%C3%A0&author=M%20Marietta&author=M%20Luongo&author=R%20Critelli&volume=143&publication_year=2012&pages=1253-1260.e4&pmid=22819864&doi=10.1053/j.gastro.2012.07.018&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B50"> <span class="label">50.</span><cite>Qi X, Dai J, Jia J, Ren W, Yang M, Li H, Fan D, Guo X. Association between portal vein thrombosis and survival of liver transplant recipients: A systematic review and meta-analysis of observational studies. J Gastrointestin Liver Dis. 2015;24:51–59, 4 p following 59. doi: 10.15403/jgld.2014.1121.qix.</cite> [<a href="https://doi.org/10.15403/jgld.2014.1121.qix" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25822434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Gastrointestin%20Liver%20Dis&title=Association%20between%20portal%20vein%20thrombosis%20and%20survival%20of%20liver%20transplant%20recipients:%20A%20systematic%20review%20and%20meta-analysis%20of%20observational%20studies&author=X%20Qi&author=J%20Dai&author=J%20Jia&author=W%20Ren&author=M%20Yang&volume=24&publication_year=2015&pages=51-59,%204%20p%20following%2059&pmid=25822434&doi=10.15403/jgld.2014.1121.qix&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B51"> <span class="label">51.</span><cite>Rodríguez-Castro KI, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: A systematic review. Transplantation. 2012;94:1145–1153. doi: 10.1097/TP.0b013e31826e8e53.</cite> [<a href="https://doi.org/10.1097/TP.0b013e31826e8e53" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23128996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&title=Management%20of%20nonneoplastic%20portal%20vein%20thrombosis%20in%20the%20setting%20of%20liver%20transplantation:%20A%20systematic%20review&author=KI%20Rodr%C3%ADguez-Castro&author=RJ%20Porte&author=E%20Nadal&author=G%20Germani&author=P%20Burra&volume=94&publication_year=2012&pages=1145-1153&pmid=23128996&doi=10.1097/TP.0b013e31826e8e53&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B52"> <span class="label">52.</span><cite>Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O. Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant. 2002;2:934–938. doi: 10.1034/j.1600-6143.2002.21009.x.</cite> [<a href="https://doi.org/10.1034/j.1600-6143.2002.21009.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12482145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&title=Eversion%20thrombectomy%20for%20portal%20vein%20thrombosis%20during%20liver%20transplantation&author=J%20Dumortier&author=O%20Czyglik&author=G%20Poncet&author=MC%20Blanchet&author=C%20Boucaud&volume=2&publication_year=2002&pages=934-938&pmid=12482145&doi=10.1034/j.1600-6143.2002.21009.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B53"> <span class="label">53.</span><cite>Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. Transplant Rev (Orlando) 2014;28:92–101. doi: 10.1016/j.trre.2014.01.003.</cite> [<a href="https://doi.org/10.1016/j.trre.2014.01.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24582320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplant%20Rev%20(Orlando)&title=Portal%20vein%20thrombosis%20and%20liver%20transplantation:%20Implications%20for%20waiting%20list%20period,%20surgical%20approach,%20early%20and%20late%20follow-up&author=FR%20Ponziani&author=MA%20Zocco&author=M%20Senzolo&author=M%20Pompili&author=A%20Gasbarrini&volume=28&publication_year=2014&pages=92-101&pmid=24582320&doi=10.1016/j.trre.2014.01.003&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B54"> <span class="label">54.</span><cite>Hernández Conde M, Llop Herrera E, de la Revilla Negro J, Pons Renedo F, Fernández Puga N, Martínez Porras JL, Trapero Marugan M, Cuervas-Mons V, Sánchez Turrión V, Calleja Panero JL. Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. Rev Esp Enferm Dig. 2016;108:716–720. doi: 10.17235/reed.2016.4211/2016.</cite> [<a href="https://doi.org/10.17235/reed.2016.4211/2016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27756145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Rev%20Esp%20Enferm%20Dig&title=Prevalence%20and%20outcome%20of%20portal%20thrombosis%20in%20a%20cohort%20of%20cirrhotic%20patients%20undergoing%20liver%20transplantation&author=M%20Hern%C3%A1ndez%20Conde&author=E%20Llop%20Herrera&author=J%20de%20la%20Revilla%20Negro&author=F%20Pons%20Renedo&author=N%20Fern%C3%A1ndez%20Puga&volume=108&publication_year=2016&pages=716-720&pmid=27756145&doi=10.17235/reed.2016.4211/2016&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B55"> <span class="label">55.</span><cite>Koh PS, Chan SC, Chok KS, Sharr WW, Wong TC, Sin SL, Lo CM. The friendly incidental portal vein thrombus in liver transplantation. Liver Transpl. 2015;21:944–952. doi: 10.1002/lt.24149.</cite> [<a href="https://doi.org/10.1002/lt.24149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25891227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&title=The%20friendly%20incidental%20portal%20vein%20thrombus%20in%20liver%20transplantation&author=PS%20Koh&author=SC%20Chan&author=KS%20Chok&author=WW%20Sharr&author=TC%20Wong&volume=21&publication_year=2015&pages=944-952&pmid=25891227&doi=10.1002/lt.24149&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B56"> <span class="label">56.</span><cite>Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203–212. doi: 10.1016/j.jhep.2011.12.034.</cite> [<a href="https://doi.org/10.1016/j.jhep.2011.12.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22446690/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&title=Portal%20vein%20thrombosis,%20cirrhosis,%20and%20liver%20transplantation&author=C%20Francoz&author=D%20Valla&author=F%20Durand&volume=57&publication_year=2012&pages=203-212&pmid=22446690&doi=10.1016/j.jhep.2011.12.034&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B57"> <span class="label">57.</span><cite>Hibi T, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, Ruiz P, Tzakis AG. When and why portal vein thrombosis matters in liver transplantation: A critical audit of 174 cases. Ann Surg. 2014;259:760–766. doi: 10.1097/SLA.0000000000000252.</cite> [<a href="https://doi.org/10.1097/SLA.0000000000000252" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24299686/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg&title=When%20and%20why%20portal%20vein%20thrombosis%20matters%20in%20liver%20transplantation:%20A%20critical%20audit%20of%20174%20cases&author=T%20Hibi&author=S%20Nishida&author=DM%20Levi&author=G%20Selvaggi&author=A%20Tekin&volume=259&publication_year=2014&pages=760-766&pmid=24299686&doi=10.1097/SLA.0000000000000252&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B58"> <span class="label">58.</span><cite>Feltracco P, Barbieri S, Cillo U, Zanus G, Senzolo M, Ori C. Perioperative thrombotic complications in liver transplantation. World J Gastroenterol. 2015;21:8004–8013. doi: 10.3748/wjg.v21.i26.8004.</cite> [<a href="https://doi.org/10.3748/wjg.v21.i26.8004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4499342/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26185371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastroenterol&title=Perioperative%20thrombotic%20complications%20in%20liver%20transplantation&author=P%20Feltracco&author=S%20Barbieri&author=U%20Cillo&author=G%20Zanus&author=M%20Senzolo&volume=21&publication_year=2015&pages=8004-8013&pmid=26185371&doi=10.3748/wjg.v21.i26.8004&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B59"> <span class="label">59.</span><cite>Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, Busuttil RW. Vascular complications of orthotopic liver transplantation: Experience in more than 4,200 patients. J Am Coll Surg. 2009;208:896–903; discussion 903-5. doi: 10.1016/j.jamcollsurg.2008.12.032.</cite> [<a href="https://doi.org/10.1016/j.jamcollsurg.2008.12.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19476857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Surg&title=Vascular%20complications%20of%20orthotopic%20liver%20transplantation:%20Experience%20in%20more%20than%204,200%20patients&author=JP%20Duffy&author=JC%20Hong&author=DG%20Farmer&author=RM%20Ghobrial&author=H%20Yersiz&volume=208&publication_year=2009&pages=896-903;%20discussion%20903-5&pmid=19476857&doi=10.1016/j.jamcollsurg.2008.12.032&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B60"> <span class="label">60.</span><cite>Senzolo M, Riva N, Dentali F, Rodriguez-Castro K, Sartori MT, Bang SM, Martinelli I, Schulman S, Alatri A, Beyer-Westendorf J, Di Minno MND, Ageno W IRSVT study investigators. Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clin Transl Gastroenterol. 2018;9:176. doi: 10.1038/s41424-018-0043-2.</cite> [<a href="https://doi.org/10.1038/s41424-018-0043-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6092393/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30108204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Transl%20Gastroenterol&title=Long-Term%20Outcome%20of%20Splanchnic%20Vein%20Thrombosis%20in%20Cirrhosis&author=M%20Senzolo&author=N%20Riva&author=F%20Dentali&author=K%20Rodriguez-Castro&author=MT%20Sartori&volume=9&publication_year=2018&pages=176&pmid=30108204&doi=10.1038/s41424-018-0043-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B61"> <span class="label">61.</span><cite>Chen H, Turon F, Hernández-Gea V, Fuster J, Garcia-Criado A, Barrufet M, Darnell A, Fondevila C, Garcia-Valdecasas JC, Garcia-Pagán JC. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transpl. 2016;22:352–365. doi: 10.1002/lt.24387.</cite> [<a href="https://doi.org/10.1002/lt.24387" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26684272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&title=Nontumoral%20portal%20vein%20thrombosis%20in%20patients%20awaiting%20liver%20transplantation&author=H%20Chen&author=F%20Turon&author=V%20Hern%C3%A1ndez-Gea&author=J%20Fuster&author=A%20Garcia-Criado&volume=22&publication_year=2016&pages=352-365&pmid=26684272&doi=10.1002/lt.24387&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B62"> <span class="label">62.</span><cite>Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44:448–451. doi: 10.1097/MCG.0b013e3181b3ab44.</cite> [<a href="https://doi.org/10.1097/MCG.0b013e3181b3ab44" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19730112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Gastroenterol&title=Safety%20and%20efficacy%20of%20anticoagulation%20therapy%20with%20low%20molecular%20weight%20heparin%20for%20portal%20vein%20thrombosis%20in%20patients%20with%20liver%20cirrhosis&author=L%20Amitrano&author=MA%20Guardascione&author=A%20Menchise&author=R%20Martino&author=M%20Scaglione&volume=44&publication_year=2010&pages=448-451&pmid=19730112&doi=10.1097/MCG.0b013e3181b3ab44&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B63"> <span class="label">63.</span><cite>Mukerji AN, Karachristos A, Maloo M, Johnson D, Jain A. Do postliver transplant patients need thromboprophylactic anticoagulation? Clin Appl Thromb Hemost. 2014;20:673–677. doi: 10.1177/1076029614538490.</cite> [<a href="https://doi.org/10.1177/1076029614538490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24917126/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Appl%20Thromb%20Hemost&title=Do%20postliver%20transplant%20patients%20need%20thromboprophylactic%20anticoagulation?&author=AN%20Mukerji&author=A%20Karachristos&author=M%20Maloo&author=D%20Johnson&author=A%20Jain&volume=20&publication_year=2014&pages=673-677&pmid=24917126&doi=10.1177/1076029614538490&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B64"> <span class="label">64.</span><cite>Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46:286–294. doi: 10.1016/j.jhep.2006.08.023.</cite> [<a href="https://doi.org/10.1016/j.jhep.2006.08.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17166617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&title=Low%20molecular%20weight%20heparin%20prevents%20hepatic%20fibrogenesis%20caused%20by%20carbon%20tetrachloride%20in%20the%20rat&author=W%20Abe&author=K%20Ikejima&author=T%20Lang&author=K%20Okumura&author=N%20Enomoto&volume=46&publication_year=2007&pages=286-294&pmid=17166617&doi=10.1016/j.jhep.2006.08.023&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B65"> <span class="label">65.</span><cite>Kopec AK, Joshi N, Towery KL, Kassel KM, Sullivan BP, Flick MJ, Luyendyk JP. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014;351:288–297. doi: 10.1124/jpet.114.218545.</cite> [<a href="https://doi.org/10.1124/jpet.114.218545" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4201275/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25138021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pharmacol%20Exp%20Ther&title=Thrombin%20inhibition%20with%20dabigatran%20protects%20against%20high-fat%20diet-induced%20fatty%20liver%20disease%20in%20mice&author=AK%20Kopec&author=N%20Joshi&author=KL%20Towery&author=KM%20Kassel&author=BP%20Sullivan&volume=351&publication_year=2014&pages=288-297&pmid=25138021&doi=10.1124/jpet.114.218545&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B66"> <span class="label">66.</span><cite>Cui SB, Shu RH, Yan SP, Wu H, Chen Y, Wang L, Zhu Q. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015;27:914–919. doi: 10.1097/MEG.0000000000000351.</cite> [<a href="https://doi.org/10.1097/MEG.0000000000000351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25856686/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Gastroenterol%20Hepatol&title=Efficacy%20and%20safety%20of%20anticoagulation%20therapy%20with%20different%20doses%20of%20enoxaparin%20for%20portal%20vein%20thrombosis%20in%20cirrhotic%20patients%20with%20hepatitis%20B&author=SB%20Cui&author=RH%20Shu&author=SP%20Yan&author=H%20Wu&author=Y%20Chen&volume=27&publication_year=2015&pages=914-919&pmid=25856686&doi=10.1097/MEG.0000000000000351&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B67"> <span class="label">67.</span><cite>Tripodi A, Primignani M, Braham S, Chantarangkul V, Clerici M, Moia M, Peyvandi F. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Dig Liver Dis. 2016;48:1208–1213. doi: 10.1016/j.dld.2016.06.027.</cite> [<a href="https://doi.org/10.1016/j.dld.2016.06.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27470055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dig%20Liver%20Dis&title=Coagulation%20parameters%20in%20patients%20with%20cirrhosis%20and%20portal%20vein%20thrombosis%20treated%20sequentially%20with%20low%20molecular%20weight%20heparin%20and%20vitamin%20K%20antagonists&author=A%20Tripodi&author=M%20Primignani&author=S%20Braham&author=V%20Chantarangkul&author=M%20Clerici&volume=48&publication_year=2016&pages=1208-1213&pmid=27470055&doi=10.1016/j.dld.2016.06.027&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B68"> <span class="label">68.</span><cite>Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26:23–29. doi: 10.1016/j.ejim.2014.12.002.</cite> [<a href="https://doi.org/10.1016/j.ejim.2014.12.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25566699/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Intern%20Med&title=Anticoagulation%20for%20the%20treatment%20of%20portal%20vein%20thrombosis%20in%20liver%20cirrhosis:%20A%20systematic%20review%20and%20meta-analysis%20of%20observational%20studies&author=X%20Qi&author=V%20De%20Stefano&author=H%20Li&author=J%20Dai&author=X%20Guo&volume=26&publication_year=2015&pages=23-29&pmid=25566699&doi=10.1016/j.ejim.2014.12.002&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B69"> <span class="label">69.</span><cite>Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;153:480–487.e1. doi: 10.1053/j.gastro.2017.04.042.</cite> [<a href="https://doi.org/10.1053/j.gastro.2017.04.042" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28479379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&title=Effects%20of%20Anticoagulants%20in%20Patients%20With%20Cirrhosis%20and%20Portal%20Vein%20Thrombosis:%20A%20Systematic%20Review%20and%20Meta-analysis&author=L%20Loffredo&author=D%20Pastori&author=A%20Farcomeni&author=F%20Violi&volume=153&publication_year=2017&pages=480-487.e1&pmid=28479379&doi=10.1053/j.gastro.2017.04.042&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B70"> <span class="label">70.</span><cite>Rodriguez-Castro KI, Vitale A, Fadin M, Shalaby S, Zerbinati P, Sartori MT, Landi S, Pettinari I, Piscaglia F, Han G, Burra P, Simioni P, Senzolo M. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol. 2019;31:34–42. doi: 10.1097/MEG.0000000000001237.</cite> [<a href="https://doi.org/10.1097/MEG.0000000000001237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30188408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Gastroenterol%20Hepatol&title=A%20prediction%20model%20for%20successful%20anticoagulation%20in%20cirrhotic%20portal%20vein%20thrombosis&author=KI%20Rodriguez-Castro&author=A%20Vitale&author=M%20Fadin&author=S%20Shalaby&author=P%20Zerbinati&volume=31&publication_year=2019&pages=34-42&pmid=30188408&doi=10.1097/MEG.0000000000001237&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B71"> <span class="label">71.</span><cite>Maruyama H, Ishibashi H, Takahashi M, Shimada T, Kamesaki H, Yokosuka O. Prediction of the therapeutic effects of anticoagulation for recent portal vein thrombosis: A novel approach with contrast-enhanced ultrasound. Abdom Imaging. 2012;37:431–438. doi: 10.1007/s00261-011-9795-9.</cite> [<a href="https://doi.org/10.1007/s00261-011-9795-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21904887/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Abdom%20Imaging&title=Prediction%20of%20the%20therapeutic%20effects%20of%20anticoagulation%20for%20recent%20portal%20vein%20thrombosis:%20A%20novel%20approach%20with%20contrast-enhanced%20ultrasound&author=H%20Maruyama&author=H%20Ishibashi&author=M%20Takahashi&author=T%20Shimada&author=H%20Kamesaki&volume=37&publication_year=2012&pages=431-438&pmid=21904887&doi=10.1007/s00261-011-9795-9&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B72"> <span class="label">72.</span><cite>La Mura V, Braham S, Tosetti G, Branchi F, Bitto N, Moia M, Fracanzani AL, Colombo M, Tripodi A, Primignani M. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol. 2018;16:1146–1152.e4. doi: 10.1016/j.cgh.2017.10.016.</cite> [<a href="https://doi.org/10.1016/j.cgh.2017.10.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29066371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&title=Harmful%20and%20Beneficial%20Effects%20of%20Anticoagulants%20in%20Patients%20With%20Cirrhosis%20and%20Portal%20Vein%20Thrombosis&author=V%20La%20Mura&author=S%20Braham&author=G%20Tosetti&author=F%20Branchi&author=N%20Bitto&volume=16&publication_year=2018&pages=1146-1152.e4&pmid=29066371&doi=10.1016/j.cgh.2017.10.016&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B73"> <span class="label">73.</span><cite>Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, Sparchez Z, Andreone P, Piscaglia F BO-LIVES (BOlogna LIVEr vascular Studies) Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol. 2019;114:258–266. doi: 10.1038/s41395-018-0421-0.</cite> [<a href="https://doi.org/10.1038/s41395-018-0421-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30538290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Gastroenterol&title=Clinical%20Impact%20and%20Safety%20of%20Anticoagulants%20for%20Portal%20Vein%20Thrombosis%20in%20Cirrhosis&author=I%20Pettinari&author=R%20Vukotic&author=H%20Stefanescu&author=A%20Pecorelli&author=M%20Morelli&volume=114&publication_year=2019&pages=258-266&pmid=30538290&doi=10.1038/s41395-018-0421-0&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B74"> <span class="label">74.</span><cite>Noronha Ferreira C, Reis D, Cortez-Pinto H, Tato Marinho R, Gonçalves A, Palma S, Leite I, Rodrigues T, Pedro AJ, Alexandrino P, Serejo F, Sobral Dias M, Ferreira P, Vasconcelos M, Damião F, Xavier Brito L, Baldaia C, Fatela N, Ramalho F, Velosa J. Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis. Dig Dis Sci. 2019 doi: 10.1007/s10620-019-05572-z.</cite> [<a href="https://doi.org/10.1007/s10620-019-05572-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30852769/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dig%20Dis%20Sci&title=Anticoagulation%20in%20Cirrhosis%20and%20Portal%20Vein%20Thrombosis%20Is%20Safe%20and%20Improves%20Prognosis%20in%20Advanced%20Cirrhosis&author=C%20Noronha%20Ferreira&author=D%20Reis&author=H%20Cortez-Pinto&author=R%20Tato%20Marinho&author=A%20Gon%C3%A7alves&publication_year=2019&pmid=30852769&doi=10.1007/s10620-019-05572-z&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B75"> <span class="label">75.</span><cite>Zhang ZH, Zhang JW, He P, Zhou Y, Sun CY. Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients. Medicine (Baltimore) 2017;96:e8256. doi: 10.1097/MD.0000000000008256.</cite> [<a href="https://doi.org/10.1097/MD.0000000000008256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5662382/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29049216/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine%20(Baltimore)&title=Fondaparinux%20is%20effective%20for%20acute%20portal%20vein%20thrombosis%20in%20decompensated%20cirrhotic%20patients&author=ZH%20Zhang&author=JW%20Zhang&author=P%20He&author=Y%20Zhou&author=CY%20Sun&volume=96&publication_year=2017&pages=e8256&pmid=29049216&doi=10.1097/MD.0000000000008256&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B76"> <span class="label">76.</span><cite>Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations. Can J Gastroenterol Hepatol. 2019;2019:4383269. doi: 10.1155/2019/4383269.</cite> [<a href="https://doi.org/10.1155/2019/4383269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6354142/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30792971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Gastroenterol%20Hepatol&title=Direct%20Oral%20Anticoagulants%20in%20Cirrhotic%20Patients:%20Current%20Evidence%20and%20Clinical%20Observations&author=S%20Elhosseiny&author=H%20Al%20Moussawi&author=JM%20Chalhoub&author=J%20Lafferty&author=L%20Deeb&volume=2019&publication_year=2019&pages=4383269&pmid=30792971&doi=10.1155/2019/4383269&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B77"> <span class="label">77.</span><cite>Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61:1721–1727. doi: 10.1007/s10620-015-4012-2.</cite> [<a href="https://doi.org/10.1007/s10620-015-4012-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26725062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dig%20Dis%20Sci&title=Direct%20Oral%20Anticoagulants%20in%20Cirrhosis%20Patients%20Pose%20Similar%20Risks%20of%20Bleeding%20When%20Compared%20to%20Traditional%20Anticoagulation&author=NM%20Intagliata&author=ZH%20Henry&author=H%20Maitland&author=NL%20Shah&author=CK%20Argo&volume=61&publication_year=2016&pages=1721-1727&pmid=26725062&doi=10.1007/s10620-015-4012-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B78"> <span class="label">78.</span><cite>Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J. Risk of drug-induced liver injury with the new oral anticoagulants: Systematic review and meta-analysis. Heart. 2014;100:550–556. doi: 10.1136/heartjnl-2013-305288.</cite> [<a href="https://doi.org/10.1136/heartjnl-2013-305288" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24476812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart&title=Risk%20of%20drug-induced%20liver%20injury%20with%20the%20new%20oral%20anticoagulants:%20Systematic%20review%20and%20meta-analysis&author=D%20Caldeira&author=M%20Barra&author=AT%20Santos&author=D%20de%20Abreu&author=FJ%20Pinto&volume=100&publication_year=2014&pages=550-556&pmid=24476812&doi=10.1136/heartjnl-2013-305288&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B79"> <span class="label">79.</span><cite>Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98:393–397. doi: 10.1111/ejh.12844.</cite> [<a href="https://doi.org/10.1111/ejh.12844" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28009449/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Haematol&title=The%20efficacy%20and%20safety%20of%20direct%20oral%20anticoagulants%20vs%20traditional%20anticoagulants%20in%20cirrhosis&author=J%20Hum&author=JJ%20Shatzel&author=JH%20Jou&author=TG%20Deloughery&volume=98&publication_year=2017&pages=393-397&pmid=28009449&doi=10.1111/ejh.12844&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B80"> <span class="label">80.</span><cite>Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2014;60:425–426. doi: 10.1002/hep.26998.</cite> [<a href="https://doi.org/10.1002/hep.26998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24395623/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Treatment%20of%20acute%20portal%20vein%20thrombosis%20by%20nontraditional%20anticoagulation&author=M%20Martinez&author=A%20Tandra&author=R%20Vuppalanchi&volume=60&publication_year=2014&pages=425-426&pmid=24395623&doi=10.1002/hep.26998&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B81"> <span class="label">81.</span><cite>Intagliata NM, Maitland H, Northup PG, Caldwell SH. Treating thrombosis in cirrhosis patients with new oral agents: Ready or not? Hepatology. 2015;61:738–739. doi: 10.1002/hep.27225.</cite> [<a href="https://doi.org/10.1002/hep.27225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24829112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=Treating%20thrombosis%20in%20cirrhosis%20patients%20with%20new%20oral%20agents:%20Ready%20or%20not?&author=NM%20Intagliata&author=H%20Maitland&author=PG%20Northup&author=SH%20Caldwell&volume=61&publication_year=2015&pages=738-739&pmid=24829112&doi=10.1002/hep.27225&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B82"> <span class="label">82.</span><cite>De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascuès C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–699. doi: 10.1111/liv.13285.</cite> [<a href="https://doi.org/10.1111/liv.13285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27778440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Int&title=Antithrombotic%20treatment%20with%20direct-acting%20oral%20anticoagulants%20in%20patients%20with%20splanchnic%20vein%20thrombosis%20and%20cirrhosis&author=A%20De%20Gottardi&author=J%20Trebicka&author=C%20Klinger&author=A%20Plessier&author=S%20Seijo&volume=37&publication_year=2017&pages=694-699&pmid=27778440&doi=10.1111/liv.13285&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B83"> <span class="label">83.</span><cite>Yang H, Kim SR, Song MJ. Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban. Clin Mol Hepatol. 2016;22:499–502. doi: 10.3350/cmh.2016.0016.</cite> [<a href="https://doi.org/10.3350/cmh.2016.0016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5266341/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27880998/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Mol%20Hepatol&title=Recurrent%20acute%20portal%20vein%20thrombosis%20in%20liver%20cirrhosis%20treated%20by%20rivaroxaban&author=H%20Yang&author=SR%20Kim&author=MJ%20Song&volume=22&publication_year=2016&pages=499-502&pmid=27880998&doi=10.3350/cmh.2016.0016&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B84"> <span class="label">84.</span><cite>Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, Morio K, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51–58. doi: 10.1111/hepr.12895.</cite> [<a href="https://doi.org/10.1111/hepr.12895" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28342265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatol%20Res&title=Efficacy%20and%20safety%20of%20edoxaban%20for%20treatment%20of%20portal%20vein%20thrombosis%20following%20danaparoid%20sodium%20in%20patients%20with%20liver%20cirrhosis&author=Y%20Nagaoki&author=H%20Aikata&author=K%20Daijyo&author=Y%20Teraoka&author=F%20Shinohara&volume=48&publication_year=2018&pages=51-58&pmid=28342265&doi=10.1111/hepr.12895&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B85"> <span class="label">85.</span><cite>Ponziani FR, De Candia E, De Cristofaro R, Pompili M. Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. Liver Int. 2017;37:1251. doi: 10.1111/liv.13406.</cite> [<a href="https://doi.org/10.1111/liv.13406" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28267885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Int&title=Portal%20vein%20thrombosis%20occurrence%20in%20a%20cirrhotic%20patient%20during%20treatment%20with%20rivaroxaban&author=FR%20Ponziani&author=E%20De%20Candia&author=R%20De%20Cristofaro&author=M%20Pompili&volume=37&publication_year=2017&pages=1251&pmid=28267885&doi=10.1111/liv.13406&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B86"> <span class="label">86.</span><cite>Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M. Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol. 2014;52:1175–1177. doi: 10.1055/s-0034-1385171.</cite> [<a href="https://doi.org/10.1055/s-0034-1385171" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25313630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Z%20Gastroenterol&title=Successful%20treatment%20of%20partial%20portal%20vein%20thrombosis%20(PVT)%20with%20low%20dose%20rivaroxaban&author=K%20Lenz&author=B%20Dieplinger&author=R%20Buder&author=P%20Piringer&author=M%20Rauch&volume=52&publication_year=2014&pages=1175-1177&pmid=25313630&doi=10.1055/s-0034-1385171&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B87"> <span class="label">87.</span><cite>Qi X, Yoshida EM, Mendez-Sanchez N, Guo X. Rivaroxaban recanalized occlusive superior mesenteric vein thrombosis, but increased the risk of bleeding in a cirrhotic patient. Liver Int. 2017;37:1574–1575. doi: 10.1111/liv.13511.</cite> [<a href="https://doi.org/10.1111/liv.13511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28675619/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Int&title=Rivaroxaban%20recanalized%20occlusive%20superior%20mesenteric%20vein%20thrombosis,%20but%20increased%20the%20risk%20of%20bleeding%20in%20a%20cirrhotic%20patient&author=X%20Qi&author=EM%20Yoshida&author=N%20Mendez-Sanchez&author=X%20Guo&volume=37&publication_year=2017&pages=1574-1575&pmid=28675619&doi=10.1111/liv.13511&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B88"> <span class="label">88.</span><cite>Pannach S, Babatz J, Beyer-Westendorf J. Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost. 2013;110:626–627. doi: 10.1160/TH13-05-0407.</cite> [<a href="https://doi.org/10.1160/TH13-05-0407" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23846289/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Haemost&title=Successful%20treatment%20of%20acute%20portal%20vein%20thrombosis%20with%20rivaroxaban&author=S%20Pannach&author=J%20Babatz&author=J%20Beyer-Westendorf&volume=110&publication_year=2013&pages=626-627&pmid=23846289&doi=10.1160/TH13-05-0407&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B89"> <span class="label">89.</span><cite>Boyer TD, Haskal ZJ American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400. doi: 10.1002/hep.20559.</cite> [<a href="https://doi.org/10.1002/hep.20559" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15660434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&title=The%20role%20of%20transjugular%20intrahepatic%20portosystemic%20shunt%20in%20the%20management%20of%20portal%20hypertension&author=TD%20Boyer&author=ZJ%20Haskal&volume=41&publication_year=2005&pages=386-400&pmid=15660434&doi=10.1002/hep.20559&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B90"> <span class="label">90.</span><cite>Madoff DC, Gaba RC, Weber CN, Clark TW, Saad WE. Portal Venous Interventions: State of the Art. Radiology. 2016;278:333–353. doi: 10.1148/radiol.2015141858.</cite> [<a href="https://doi.org/10.1148/radiol.2015141858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26789601/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&title=Portal%20Venous%20Interventions:%20State%20of%20the%20Art&author=DC%20Madoff&author=RC%20Gaba&author=CN%20Weber&author=TW%20Clark&author=WE%20Saad&volume=278&publication_year=2016&pages=333-353&pmid=26789601&doi=10.1148/radiol.2015141858&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B91"> <span class="label">91.</span><cite>Rodrigues SG, Sixt S, Abraldes JG, De Gottardi A, Klinger C, Bosch J, Baumgartner I, Berzigotti A. Systematic review with meta-analysis: Portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019;49:20–30. doi: 10.1111/apt.15044.</cite> [<a href="https://doi.org/10.1111/apt.15044" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30450634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aliment%20Pharmacol%20Ther&title=Systematic%20review%20with%20meta-analysis:%20Portal%20vein%20recanalisation%20and%20transjugular%20intrahepatic%20portosystemic%20shunt%20for%20portal%20vein%20thrombosis&author=SG%20Rodrigues&author=S%20Sixt&author=JG%20Abraldes&author=A%20De%20Gottardi&author=C%20Klinger&volume=49&publication_year=2019&pages=20-30&pmid=30450634&doi=10.1111/apt.15044&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B92"> <span class="label">92.</span><cite>Wang Z, Jiang MS, Zhang HL, Weng NN, Luo XF, Li X, Yang L. Is Post-TIPS Anticoagulation Therapy Necessary in Patients with Cirrhosis and Portal Vein Thrombosis? A Randomized Controlled Trial. Radiology. 2016;279:943–951. doi: 10.1148/radiol.2015150369.</cite> [<a href="https://doi.org/10.1148/radiol.2015150369" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26653681/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&title=Is%20Post-TIPS%20Anticoagulation%20Therapy%20Necessary%20in%20Patients%20with%20Cirrhosis%20and%20Portal%20Vein%20Thrombosis?%20A%20Randomized%20Controlled%20Trial&author=Z%20Wang&author=MS%20Jiang&author=HL%20Zhang&author=NN%20Weng&author=XF%20Luo&volume=279&publication_year=2016&pages=943-951&pmid=26653681&doi=10.1148/radiol.2015150369&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B93"> <span class="label">93.</span><cite>Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, Hickey R, Habib A, Abecassis M, Koller F, Vogelzang R, Desai K, Thornburg B, Hohlastos E, Resnick S, Lewandowski RJ, Sato K, Ryu RK, Ganger D, Kulik L. Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis. Transplantation. 2015;99:2347–2355. doi: 10.1097/TP.0000000000000729.</cite> [<a href="https://doi.org/10.1097/TP.0000000000000729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25905983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&title=Pretransplant%20Portal%20Vein%20Recanalization-Transjugular%20Intrahepatic%20Portosystemic%20Shunt%20in%20Patients%20With%20Complete%20Obliterative%20Portal%20Vein%20Thrombosis&author=R%20Salem&author=M%20Vouche&author=T%20Baker&author=JI%20Herrero&author=JC%20Caicedo&volume=99&publication_year=2015&pages=2347-2355&pmid=25905983&doi=10.1097/TP.0000000000000729&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B94"> <span class="label">94.</span><cite>Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, Vizzini G, Tuzzolino F, Gridelli B, Bosch J. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut. 2011;60:846–852. doi: 10.1136/gut.2010.228023.</cite> [<a href="https://doi.org/10.1136/gut.2010.228023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21357252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&title=Short-%20and%20long-term%20effects%20of%20the%20transjugular%20intrahepatic%20portosystemic%20shunt%20on%20portal%20vein%20thrombosis%20in%20patients%20with%20cirrhosis&author=A%20Luca&author=R%20Miraglia&author=S%20Caruso&author=M%20Milazzo&author=C%20Sapere&volume=60&publication_year=2011&pages=846-852&pmid=21357252&doi=10.1136/gut.2010.228023&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B95"> <span class="label">95.</span><cite>Barbier L, Hardwigsen J, Borentain P, Biance N, Daghfous A, Louis G, Botta-Fridlund D, Le Treut YP. Impact of transjugular intrahepatic portosystemic shunting on liver transplantation: 12-year single-center experience. Clin Res Hepatol Gastroenterol. 2014;38:155–163. doi: 10.1016/j.clinre.2013.09.003.</cite> [<a href="https://doi.org/10.1016/j.clinre.2013.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24183545/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Res%20Hepatol%20Gastroenterol&title=Impact%20of%20transjugular%20intrahepatic%20portosystemic%20shunting%20on%20liver%20transplantation:%2012-year%20single-center%20experience&author=L%20Barbier&author=J%20Hardwigsen&author=P%20Borentain&author=N%20Biance&author=A%20Daghfous&volume=38&publication_year=2014&pages=155-163&pmid=24183545&doi=10.1016/j.clinre.2013.09.003&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B96"> <span class="label">96.</span><cite>Guerrini GP, Pleguezuelo M, Maimone S, Calvaruso V, Xirouchakis E, Patch D, Rolando N, Davidson B, Rolles K, Burroughs A. Impact of tips preliver transplantation for the outcome posttransplantation. Am J Transplant. 2009;9:192–200. doi: 10.1111/j.1600-6143.2008.02472.x.</cite> [<a href="https://doi.org/10.1111/j.1600-6143.2008.02472.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19067664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&title=Impact%20of%20tips%20preliver%20transplantation%20for%20the%20outcome%20posttransplantation&author=GP%20Guerrini&author=M%20Pleguezuelo&author=S%20Maimone&author=V%20Calvaruso&author=E%20Xirouchakis&volume=9&publication_year=2009&pages=192-200&pmid=19067664&doi=10.1111/j.1600-6143.2008.02472.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B97"> <span class="label">97.</span><cite>Baccarani U, Gasparini D, Risaliti A, Vianello V, Adani GL, Sainz M, Sponza M, Bresadola F. Percutaneous mechanical fragmentation and stent placement for the treatment of early posttransplantation portal vein thrombosis. Transplantation. 2001;72:1572–1582. doi: 10.1097/00007890-200111150-00016.</cite> [<a href="https://doi.org/10.1097/00007890-200111150-00016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11707747/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&title=Percutaneous%20mechanical%20fragmentation%20and%20stent%20placement%20for%20the%20treatment%20of%20early%20posttransplantation%20portal%20vein%20thrombosis&author=U%20Baccarani&author=D%20Gasparini&author=A%20Risaliti&author=V%20Vianello&author=GL%20Adani&volume=72&publication_year=2001&pages=1572-1582&pmid=11707747&doi=10.1097/00007890-200111150-00016&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B98"> <span class="label">98.</span><cite>Lodhia N, Salem R, Levitsky J. Transjugular intrahepatic portosystemic shunt with thrombectomy for the treatment of portal vein thrombosis after liver transplantation. Dig Dis Sci. 2010;55:529–534. doi: 10.1007/s10620-009-0735-2.</cite> [<a href="https://doi.org/10.1007/s10620-009-0735-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19242796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dig%20Dis%20Sci&title=Transjugular%20intrahepatic%20portosystemic%20shunt%20with%20thrombectomy%20for%20the%20treatment%20of%20portal%20vein%20thrombosis%20after%20liver%20transplantation&author=N%20Lodhia&author=R%20Salem&author=J%20Levitsky&volume=55&publication_year=2010&pages=529-534&pmid=19242796&doi=10.1007/s10620-009-0735-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> </ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless"> <p>Articles from World Journal of Gastroenterology are provided here courtesy of <strong>Baishideng Publishing Group Inc</strong></p></footer></section></article> </main> </div> </div> </div>  <div class="pmc-sidenav desktop:grid-col-4 display-flex"> <section class="pmc-sidenav__container" aria-label="Article resources and navigation"> <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled"> <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" /> </button> <div class="display-none desktop:display-block"> <section class="margin-top-4 desktop:margin-top-0"> <h2 class="margin-top-0">ACTIONS</h2> <ul class="usa-list usa-list--unstyled usa-list--actions"> <li> <a href="https://doi.org/10.3748/wjg.v25.i31.4437" class="usa-button usa-button--outline width-24 font-xs usa-link--external padding-left-0 padding-right-0" target="_blank" rel="noreferrer noopener" data-ga-category="actions" data-ga-action="click" data-ga-label="publisher_link_desktop" > <span class="height-3 display-inline-flex flex-align-center">View on publisher site</span> </a> </li> <li> <a href="pdf/WJG-25-4437.pdf" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">PDF (435.1 KB)</span> </a> </li> <li> <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_desktop" data-all-citations-url="/resources/citations/6710174/" data-citation-style="nlm" data-download-format-link="/resources/citations/6710174/export/" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span> </button> </li> <li> <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_desktop" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6710174%2F%23open-collections-dialog" data-in-collections="false"> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">Collections</span> </button> </li> <li class="pmc-permalink"> <button type="button" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6710174/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC6710174/"> <h2 class="margin-top-0">RESOURCES</h2> <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-similar-articles" data-ga-category="resources_accordion" data-ga-action="open_similar_articles" data-ga-label="/articles/PMC6710174/" data-action-open="open_similar_articles" data-action-close="close_similar_articles" > Similar articles </button> </h3> <div id="resources-similar-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/similar-article-links/31496623/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-cited-by-other-articles" data-ga-category="resources_accordion" data-ga-action="open_cited_by" data-ga-label="/articles/PMC6710174/" data-action-open="open_cited_by" data-action-close="close_cited_by" > Cited by other articles </button> </h3> <div id="resources-cited-by-other-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/cited-by-links/31496623/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-links-to-ncbi-databases" data-ga-category="resources_accordion" data-ga-action="open_NCBI_links" data-ga-label="/articles/PMC6710174/" data-action-open="open_NCBI_links" data-action-close="close_NCBI_link" > Links to NCBI Databases </button> </h3> <div id="resources-links-to-ncbi-databases" class="usa-accordion__content usa-prose" data-source-url="/resources/db-links/6710174/" > </div> </div> </section> <section class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4" data-title-text="On this page" data-title-heading-level="h2" data-scroll-offset="0" data-root-margin="-10% 0px -80% 0px" data-main-content-selector="main" data-threshold="1" hidden ></section> </section> </div> <div class="overlay" role="dialog" aria-label="Citation Dialog" hidden> <div class="dialog citation-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Cite</h2> <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto" tabindex="1"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="citation-text-block"> <div class="citation-text margin-bottom-2"></div> <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center"> <li> <button class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus" data-ga-category="save_share" data-ga-action="cite" data-ga-label="copy" tabindex="2"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span>Copy</span> </button> </li> <li> <a href="#" role="button" class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button" data-ga-category="save_share" data-ga-action="cite" data-ga-label="download" title="Download a file for external citation management software" tabindex="3"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-none mobile-lg:display-inline">Download .nbib</span> <span class="display-inline mobile-lg:display-none">.nbib</span> </a> </li> <li> <div class="display-inline-flex flex-align-center"> <label class="usa-label margin-top-0">Format:</label> <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" > <option data-style-url-name="ama" value="AMA" > AMA </option> <option data-style-url-name="apa" value="APA" > APA </option> <option data-style-url-name="mla" value="MLA" > MLA </option> <option data-style-url-name="nlm" value="NLM" selected="selected"> NLM </option> </select> </div> </li> </ul> </div> </div> </div> <div class="overlay" role="dialog" hidden> <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Add to Collections</h2> </div> <div class="collections-action-panel action-panel"> <form id="collections-action-dialog-form" class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors" data-existing-collections-url="/list-existing-collections/" data-add-to-existing-collection-url="/add-to-existing-collection/" data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/" data-myncbi-max-collection-name-length="100" data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/"> <input type="hidden" name="csrfmiddlewaretoken" value="VpSnYqfCk84jPyXmOCIBnAZ50GIGMeS6xUqMszq6vtl2A0QNGah3GwowIzL8X26D"> <fieldset class="usa-fieldset margin-bottom-2"> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-new" class="usa-radio__input usa-radio__input--tile collections-new margin-top-0" name="collections" value="new" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_new" /> <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label> </div> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-existing" class="usa-radio__input usa-radio__input--tile collections-existing" name="collections" value="existing" checked="true" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_existing" /> <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label> </div> </fieldset> <fieldset class="usa-fieldset margin-bottom-2"> <div class="action-panel-control-wrap new-collections-controls"> <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0"> Name your collection <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr> </label> <input type="text" name="add-to-new-collection" id="collections-action-dialog-add-to-new" class="usa-input collections-action-add-to-new" pattern="[^"&=<>/]*" title="The following characters are not allowed in the Name field: "&=<>/" maxlength="" data-ga-category="collections_button" data-ga-action="create_collection" data-ga-label="non_favorties_collection" required /> </div> <div class="action-panel-control-wrap existing-collections-controls"> <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0"> Choose a collection </label> <select id="collections-action-dialog-add-to-existing" class="usa-select collections-action-add-to-existing" data-ga-category="collections_button" data-ga-action="select_collection" data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'"> </select> <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message"> Unable to load your collection due to an error<br> <a href="#">Please try again</a> </div> </div> </fieldset> <div class="display-inline-flex"> <button class="usa-button margin-top-0 action-panel-submit" type="submit" data-loading-label="Adding..." data-pinger-ignore data-ga-category="collections_button" data-ga-action="click" data-ga-label="add"> Add </button> <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel" aria-label="Close 'Add to Collections' panel" ref="linksrc=close_collections_panel" data-ga-category="collections_button" data-ga-action="click" data-ga-label="cancel"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class="ncbi-footer ncbi-dark-background " > <div class="ncbi-footer__icon-section"> <div class="ncbi-footer__social-header"> Follow NCBI </div> <div class="grid-container ncbi-footer__ncbi-social-icons-container"> <a href="https://twitter.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="40" height="40" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span> </a> <a href="https://www.facebook.com/ncbi.nlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="16" height="29" focusable="false" aria-hidden="true" viewBox="0 0 16 29" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z"> </path> </svg> <span class="usa-sr-only">NCBI on Facebook</span> </a> <a href="https://www.linkedin.com/company/ncbinlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="25" height="23" viewBox="0 0 26 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z"> </path> <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z"> </path> <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z"> </path> </svg> <span class="usa-sr-only">NCBI on LinkedIn</span> </a> <a href="https://github.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="28" height="27" viewBox="0 0 28 28" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z"> </path> </svg> <span class="usa-sr-only">NCBI on GitHub</span> </a> <a href="https://ncbiinsights.ncbi.nlm.nih.gov/" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="26" height="26" viewBox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z"> </path> <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z"> </path> <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z"> </path> </svg> <span class="usa-sr-only">NCBI RSS feed</span> </a> </div> </div> <div data-testid="gridContainer" class="grid-container ncbi-footer__container"> <div class="grid-row ncbi-footer__main-content-container" data-testid="grid"> <div class="ncbi-footer__column"> <p class="ncbi-footer__circled-icons-heading"> Connect with NLM </p> <div class="ncbi-footer__circled-icons-list"> <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="32" height="32" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span> </a> <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="13" height="24" viewBox="0 0 13 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z"> </path> </svg> <span class="usa-sr-only">NLM on Facebook</span> </a> <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="21" height="15" viewBox="0 0 21 15" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z" fill="white" /> </svg> <span class="usa-sr-only">NLM on YouTube</span> </a> </div> </div> <address class="ncbi-footer__address ncbi-footer__column"> <p> <a class="usa-link usa-link--external" href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323" rel="noopener noreferrer" target="_blank">National Library of Medicine <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a> </p> </address> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link usa-link--alt ncbi-footer__link" > Web Policies </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link usa-link--alt ncbi-footer__link" > FOIA </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS Vulnerability Disclosure </a> </li> </ul> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://support.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > Help </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link usa-link--alt ncbi-footer__link" > Accessibility </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link usa-link--alt ncbi-footer__link" > Careers </a> </li> </ul> </div> <div class="grid-row grid-col-12" data-testid="grid"> <ul class="ncbi-footer__bottom-links-list"> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NLM </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NIH </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > USA.gov </a> </li> </ul> </div> </div> </footer> <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script> <button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top"> <label>Back to Top</label> <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#arrow_upward"></use> </svg> </button> <script src="https://code.jquery.com/jquery-3.5.0.min.js" integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ=" crossorigin="anonymous"> </script> <script type="text/javascript">var exports = {};</script> <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script> <script type="application/javascript"> window.ncbi = window.ncbi || {}; window.ncbi.pmc = window.ncbi.pmc || {}; window.ncbi.pmc.options = { logLevel: 'INFO', staticEndpoint: '/static/', citeCookieName: 'pmc-cf', }; </script> <script type="module" crossorigin="" src="/static/assets/base-9bea7450.js"></script> <script type="module" crossorigin="" src="/static/assets/article-722d91a2.js"></script> </body> </html>

CINXE.COM

Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate - PMC